

# CITATION REPORT

List of articles citing

**Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer**

**DOI: 10.1126/science.aaa1348**  
**Science, 2015, 348, 124-8.**

**Source:** <https://exaly.com/paper-pdf/62283544/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2222	Current state of immunotherapy for non-small cell lung cancer. <b>2017</b> , 6, 196-211		107
2221	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <b>2017</b> , 6, 169-177		2
2220	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. <b>2017</b> , 6, 186-195		8
2219	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. <b>2017</b> , 6, 220-229		9
2218	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. <b>2017</b> , 6, 113-118		11
2217	Integration der Genomsequenzierung in die klinische Hämat-Onkologie [Eine Möglichkeit für Personalisierte Therapien. <b>2015</b> , 44, 436-440		
2216	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <b>2015</b> , 10, 1726-35		155
2215	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. <b>2015</b> , 126, 1203-13		71
2214	Expanding the peptidome for immunotherapy. <b>2015</b> , 126, 1154-6		0
2213	FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. <b>2015</b> , 1, 15049		29
2212	Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?. <b>2015</b> , 8, 124		20
2211	An der Schwelle zu einem neuen Zeitalter. <b>2015</b> , 18, 96-97		
2210	JITC launches a new section: commentary and editorials. <b>2015</b> , 3, 28		
2209	Targeted Therapy for Cancer in the Genomic Era. <b>2015</b> , 21, 294-8		34
2208	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. <b>2015</b> , 13, 247		45
2207	Integrating tumor microenvironment with cancer molecular classifications. <b>2015</b> , 7, 115		2
2206	Spontaneous regression of non-small cell lung cancer after biopsy of a mediastinal lymph node metastasis: a case report. <b>2015</b> , 9, 217		19

2205	Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. <b>2015</b> , 4, 34	18
2204	Update on checkpoint blockade therapy for lymphoma. <b>2015</b> , 3, 33	10
2203	Inhibitory receptors as targets for cancer immunotherapy. <b>2015</b> , 45, 1892-905	84
2202	Immunotherapy for Advanced Lung Cancer. <b>2015</b> , 21, 383-91	6
2201	Group 1 CD1-restricted T cells and the pathophysiological implications of self-lipid antigen recognition. <b>2015</b> , 86, 393-405	12
2200	Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer. <b>2015</b> , 46, 1541-3	3
2199	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. <b>2015</b> , 27, 482-8	24
2198	Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies. <b>2015</b> , 22, 489-96	2
2197	Immunotherapies for bladder cancer: a new hope. <b>2015</b> , 25, 586-96	13
2196	Management of Small Cell Lung Cancer: Progress and Updates. <b>2015</b> , 21, 425-33	18
2195	Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions. <b>2015</b> , 21, 450-64	30
2194	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. <b>2015</b> , 6, 34221-7	163
2193	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <b>2015</b> , 125, 3413-21	370
2192	Biomarkers of Response to Immune Modulatory Therapies in Cancer. <b>2015</b> , 06,	
2191	Drug Development for Metastasis Prevention. <b>2015</b> , 20, 449-73	21
2190	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. <b>2015</b> , 3, 420-8	14
2189	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. <b>2015</b> , 3, 490-502	35
2188	Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. <b>2015</b> , 3, 597-619	38

2187	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <b>2015</b> , 6, 516	51
2186	Immunotherapy of Childhood Sarcomas. <b>2015</b> , 5, 181	44
2185	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <b>2015</b> , 10, e0130142	339
2184	A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. <b>2015</b> , 6, 44781-93	85
2183	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. <b>2015</b> , 2015, 595363	17
2182	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. <b>2015</b> , 34, 313-21	26
2181	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. <b>2015</b> , 125, 3981-91	257
2180	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <b>2015</b> , 372, 2509-20	5560
2179	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <b>2015</b> , 373, 123-35	5539
2178	T cell exclusion, immune privilege, and the tumor microenvironment. <i>Science</i> , <b>2015</b> , 348, 74-80	33.3 1156
2177	PD-1/PD-L1 inhibitors. <b>2015</b> , 23, 32-8	358
2176	Lung cancer in the era of precision medicine. <b>2015</b> , 21, 2213-20	109
2175	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. <b>2015</b> , 26, 1488-93	179
2174	Rearranging Detection of Gene Rearrangements. <b>2015</b> , 10, 1129-30	
2173	Adoptive T-cell therapy for cancer: The era of engineered T cells. <b>2015</b> , 45, 2457-69	60
2172	Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer. <b>2015</b> , 33, 3845-6	1
2171	Retargeted oncolytic viruses provoke tumor-directed T-cell responses. <b>2015</b> , 4, e1052933	5
2170	Predictive biomarkers for checkpoints, first tests approved. <b>2015</b> , 33, 1217-1218	12

2169	Promise of Immunotherapy in Lung Cancer. <b>2015</b> , 42, 95-109	1
2168	Systematic pan-cancer analysis of tumour purity. <b>2015</b> , 6, 8971	555
2167	Overcoming Antigen Escape with CAR T-cell Therapy. <b>2015</b> , 5, 1238-40	50
2166	Lung cancer. <b>2015</b> , 4, 117-123	
2165	Prognostic and predictive immune gene signatures in breast cancer. <b>2015</b> , 27, 433-44	57
2164	New hope on the horizon for patients with metastatic colorectal cancer. <b>2015</b> , 4, 229-239	
2163	[What opportunities does Immuno-oncology indicate for overarching long-term survival?]. <b>2015</b> , 38 Suppl 3, 6-11	1
2162	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. <b>2015</b> , 75, 3800-11	151
2161	The more tumors change, the more they stay tame: do T cells keep POLE ultramutated endometrial carcinomas in check?. <b>2015</b> , 138, 1-2	11
2160	[New immunotherapeutic approaches in oncology and hematology]. <b>2015</b> , 22, 132-40	1
2159	[Immunological tumor therapy]. <b>2015</b> , 56, 907-16; quiz 917	5
2158	Cancer immunotherapy: exploiting neoepitopes. <b>2015</b> , 25, 887-8	18
2157	New immunotherapies targeting the PD-1 pathway. <b>2015</b> , 36, 587-95	120
2156	Inflammation and Lung Cancer. <b>2015</b> ,	0
2155	Cancer immunotherapy out of the gate: the 22nd annual Cancer Research Institute International Immunotherapy Symposium. <b>2015</b> , 3, 444-8	2
2154	Challenges and future perspectives of T cell immunotherapy in cancer. <b>2015</b> , 166, 117-33	37
2153	Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. <b>2015</b> , 28, 11-3	62
2152	Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. <b>2015</b> , 64, 1193-203	14

2151	Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens. <b>2015</b> , 12, 533-41		22
2150	The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. <b>2015</b> , 463, 551-6		104
2149	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. <b>2015</b> , 51, 1803-11		26
2148	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <b>2015</b> , 15, 457-72		447
2147	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. <b>2015</b> , 5, 704-12		267
2146	In-situ tumor vaccination: Bringing the fight to the tumor. <b>2015</b> , 11, 1901-9		49
2145	Opportunities and challenges of radiotherapy for treating cancer. <b>2015</b> , 12, 527-40		245
2144	The future of immune checkpoint therapy. <i>Science</i> , <b>2015</b> , 348, 56-61	33.3	2733
2143	Neoantigens in cancer immunotherapy. <i>Science</i> , <b>2015</b> , 348, 69-74	33.3	2790
2142	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. <b>2015</b> , 520, 692-6		698
2141	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <b>2015</b> , 372, 2521-32		3792
2140	Cancer immunotherapy. Neo approaches to cancer vaccines. <i>Science</i> , <b>2015</b> , 348, 760-1	33.3	37
2139	Small cell lung cancer: will recent progress lead to improved outcomes?. <b>2015</b> , 21, 2244-55		129
2138	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <b>2015</b> , 373, 1627-39		5964
2137	PD-1 and PD-L1 blockade in gastrointestinal malignancies. <b>2015</b> , 41, 893-903		44
2136	Genetics and immunology: reinvigorated. <b>2015</b> , 4, e1029705		7
2135	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. <b>2015</b> , 26, 2470-7		15
2134	Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. <b>2015</b> , 195, 4028-37		18

2133	Predictors of clinical response to immunotherapy with or without radiotherapy. <b>2015</b> , 4, 339-345	11
2132	Immunomodulation: checkpoint blockade etc. <b>2015</b> , 17 Suppl 7, vii26-vii31	18
2131	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <b>2015</b> , 9, 2043-53	68
2130	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <b>2015</b> , 17 Suppl 7, vii32-vii40	15
2129	Targeting Programmed Cell Death 1 in Ovarian Cancer. <b>2015</b> , 33, 3987-9	16
2128	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. <b>2015</b> , 42, 775-87	4
2127	Practical Approaches to Immunotherapy in the Clinic. <b>2015</b> , 42 Suppl 3, S20-7	8
2126	New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. <b>2015</b> , 21, 5191-7	24
2125	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <b>2015</b> , 15, 668-79	581
2124	The path to routine use of genomic biomarkers in the cancer clinic. <b>2015</b> , 25, 1508-13	26
2123	Immunogenicity of somatic mutations in human gastrointestinal cancers. <i>Science</i> , <b>2015</b> , 350, 1387-90	33.3 465
2122	Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. <b>2015</b> , 290, 26562-75	45
2121	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. <b>2015</b> , 15, 1491-500	4
2120	Genomic spectra of biliary tract cancer. <b>2015</b> , 47, 1003-10	612
2119	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <b>2015</b> , 11, 504-14	240
2118	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. <b>2015</b> , 7, 777-92	16
2117	Academically led clinical trials: challenges and opportunities. <b>2015</b> , 26, 2010-1	1
2116	Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015. <b>2015</b> , 64, 1071-4	4

2115	Lung cancer nanomedicine: potentials and pitfalls. <b>2015</b> , 10, 3203-12	42
2114	Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung. <b>2015</b> , 5, 272-4	6
2113	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. <b>2015</b> , 26, 2367-74	33
2112	Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. <b>2015</b> , 42 Suppl 2, S19-28	16
2111	Oral cancer breaks out at ASCO. <b>2015</b> , 120, 421-3	0
2110	Gene therapy returns to centre stage. <b>2015</b> , 526, 351-60	783
2109	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. <b>2015</b> , 42 Suppl 2, S11-8	47
2108	Next-Generation Sequencing to Guide Clinical Trials. <b>2015</b> , 21, 4536-44	44
2107	Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. <b>2015</b> , 26, 2429-36	82
2106	CANCER. The odds of immunotherapy success. <i>Science</i> , <b>2015</b> , 350, 158-9	33-3 70
2105	Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. <b>2015</b> , 21, 4251-3	1
2104	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. <b>2015</b> , 7, 981-97	3
2103	Manipulating the in vivo immune response by targeted gene knockdown. <b>2015</b> , 35, 63-72	7
2102	Lung cancer: Biology and treatment options. <b>2015</b> , 1856, 189-210	322
2101	Current and future molecular profiling of cancer by next-generation sequencing. <b>2015</b> , 45, 895-9	11
2100	Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon. <b>2015</b> , 22, 3459-65	4
2099	Pembrolizumab. <b>2015</b> , 3, 36	131
2098	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <b>2015</b> , 162, 974-86	872



2097	Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. <b>2015</b> , 11, 2790-5	43
2096	Immune Checkpoint Inhibitors. <b>2015</b> , 42, 55-66	93
2095	Immunopharmacogenomics. <b>2015</b> ,	3
2094	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <b>2015</b> , 162, 1242-56	365
2093	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , <b>2015</b> , 350, 207-211	1583
2092	The emergence of immuno-oncology companion products. <b>2015</b> , 12, 435-438	3
2091	AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting. <b>2015</b> , 782, 44-51	7
2090	Landscape of Tumor Antigens in T Cell Immunotherapy. <b>2015</b> , 195, 5117-22	100
2089	Active Immunotherapy of Cancer. <b>2015</b> , 44, 817-36	32
2088	Nivolumab for treating non-small cell lung cancer. <b>2015</b> , 15, 1789-97	19
2087	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. <b>2015</b> , 41, 868-76	280
2086	Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery. <b>2015</b> , 3, 1195-200	27
2085	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. <b>2015</b> , 9, 2054-62	60
2084	Immunotherapy in Colorectal Cancer. <b>2016</b> ,	
2083	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. <b>2016</b> , 8, E1348-E1350	
2082	CD8 T Lymphocytes in Antitumor Immunity. <b>2016</b> , 434-440	
2081	Immuntherapien beim Mammakarzinom [Wie hängen Immunsystem und Krebs zusammen und woran arbeitet die Forschung?]. <b>2016</b> , 13, 169-172	
2080	Genomic characterization of high-risk non-muscle invasive bladder cancer. <b>2016</b> , 7, 75176-75184	45

2079	The steady progress of targeted therapies, promising advances for lung cancer. <b>2016</b> , 10, 638	6
2078	[Molekulargenetische Diagnostik - Was wissen die Maschinen? Was wollen wir wissen?]. <b>2016</b> , 39 Suppl 2, 2-23	
2077	Neoantigen-based cancer immunotherapy. <b>2016</b> , 4, 262	55
2076	Checkpoint Inhibitors for Advanced Bladder Cancer. <b>2016</b> , 2, 473-474	1
2075	Immuno-oncology combinations: raising the tail of the survival curve. <b>2016</b> , 13, 171-93	67
2074	The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. <b>2016</b> , 7, 3477-88	51
2073	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. <b>2016</b> , 7, 32113-28	81
2072	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. <b>2016</b> , 9, 5855-5866	8
2071	Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. <b>2016</b> , 17,	16
2070	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. <b>2016</b> , 13, 157-70	60
2069	Targeted therapies and immunotherapy in non-small-cell lung cancer. <b>2016</b> , 10, 648	20
2068	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. <b>2016</b> , 9, 3187-95	11
2067	New targeted treatments for non-small-cell lung cancer - role of nivolumab. <b>2016</b> , 10, 103-17	18
2066	Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics. <b>2016</b> , 12, 74-117	2
2065	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability . PD-L1. <b>2016</b> , 7, 771-788	61
2064	Seeking New Approaches to Patients With Small Cell Lung Cancer. <b>2016</b> , 35, e477-82	2
2063	Current State of Immune-Based Therapies for Glioblastoma. <b>2016</b> , 35, e132-9	8
2062	From the era of ineffective tumor vaccines to a future with effective immunotherapy. <b>2016</b> , 8, 1916-7	

2061	The head and neck cancer immune landscape and its immunotherapeutic implications. <b>2016</b> , 1, e89829	356
2060	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. <b>2016</b> , 7, 3403-15	229
2059	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. <b>2016</b> , 7, 32925-32	191
2058	Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. <b>2016</b> , 35, e175-84	8
2057	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. <b>2016</b> , 12, 649-50	5
2056	Biomarkers for Immunotherapy: Current Developments and Challenges. <b>2016</b> , 35, e493-503	61
2055	Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. <b>2016</b> , 35, e558-64	8
2054	PD-L1 expression in lung cancer. <b>2016</b> , 8, 3053-3055	1
2053	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. <b>2016</b> , 5, 628-636	12
2052	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <b>2016</b> , 5, 720-726	24
2051	Genomic landscape of DNA repair genes in cancer. <b>2016</b> , 7, 23312-21	101
2050	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <b>2016</b> , 5, 301-21	33
2049	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. <b>2016</b> , 7, 37331-37346	59
2048	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. <b>2016</b> , 1, e87415	89
2047	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <b>2016</b> , 7, 10051-63	169
2046	Advances in targeted therapy and immunotherapy for treatment of lung cancer. <b>2016</b> , 24, 1-6	1
2045	Aptamers: A Feasible Technology in Cancer Immunotherapy. <b>2016</b> , 2016, 1083738	22
2044	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. <b>2016</b> , 2016, 9850690	15

2043	Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. <b>2016</b> , 7, 1599-1604	7
2042	Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer. <b>2016</b> , 7, 29-34	1
2041	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. <b>2016</b> , 6, 1629-40	138
2040	PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN- $\gamma$ and Can Be Expressed in the Tumor Microenvironment. <b>2016</b> , 7, 581	29
2039	Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. <b>2016</b> , 7, 610	87
2038	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <b>2016</b> , 7, 621	90
2037	Focus on Nivolumab in NSCLC. <b>2016</b> , 3, 67	3
2036	Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. <b>2016</b> , 6, 212	26
2035	Recent Advances in Immunotherapy in Metastatic NSCLC. <b>2016</b> , 6, 239	23
2034	Advances in Cancer Immunotherapy in Solid Tumors. <b>2016</b> , 8,	109
2033	Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples. <b>2016</b> , 17,	40
2032	Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling-Project HOPE. <b>2016</b> , 37, 233-42	9
2031	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. <b>2016</b> , 11, e0153954	53
2030	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. <b>2016</b> , 11, e0155189	77
2029	Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications. <b>2016</b> , 3, 40	42
2028	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. <b>2016</b> , 9, 5101-16	26
2027	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. <b>2016</b> , 2, 15-25	21
2026	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. <b>2016</b> , 7, 74350-74361	31

2025	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <b>2016</b> , 4, 215	6
2024	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <b>2016</b> , 7, 73068-73079	60
2023	Integration der Genomsequenzierung in die klinische Hämato-Onkologie [Eine Möglichkeit für personalisierte Therapien. <b>2016</b> , 37, 332-336	
2022	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. <b>2016</b> , 22, 101-7	17
2021	MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. <b>2016</b> , 28, 195-200	22
2020	Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. <b>2016</b> , 98, 114-117	99
2019	Pembrolizumab (Keytruda). <b>2016</b> , 12, 2777-2789	127
2018	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <b>2016</b> , 21, 974-80	52
2017	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. <b>2016</b> , 8, 809-19	39
2016	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <b>2016</b> , 8, 907-21	16
2015	Future directions in the treatment of osteosarcoma. <b>2016</b> , 28, 26-33	179
2014	Immune Checkpoint Therapy in Non-Small Cell Lung Cancer. <b>2016</b> , 22, 81-91	7
2013	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. <b>2016</b> , 22, 68-72	26
2012	Agility in adversity: Vaccines on Demand. <b>2016</b> , 15, 1087-91	5
2011	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <b>2016</b> , 22, 4309-21	127
2010	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. <b>2016</b> , 48, 61-8	77
2009	Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer. <b>2016</b> , 42, 1680-1686	30
2008	Intratumoral expression levels of , , and along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. <b>2016</b> , 5, e1204507	87

2007	Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis. <b>2016</b> , 38, 1234-41	11
2006	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. <b>2016</b> , 101, 794-802	62
2005	Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. <b>2016</b> , 197, 1477-88	24
2004	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <b>2016</b> , 34, 2969-79	322
2003	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <b>2016</b> , 34, 2980-7	338
2002	Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer. <b>2016</b> , 34, 2953-5	11
2001	Novel Targets and Their Assessment for Cancer Treatment. <b>2016</b> , 163-180	
2000	Precision medicine for advanced prostate cancer. <b>2016</b> , 26, 231-9	21
1999	Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. <b>2016</b> , 17, 507-516	36
1998	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <b>2016</b> , 115, 252-60	51
1997	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. <b>2016</b> , 18, 1357-66	97
1996	Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. <b>2016</b> , 122, 367-77	96
1995	The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. <b>2016</b> , 100, 212-4	19
1994	Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. <b>2016</b> , 46, 1351-60	23
1993	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. <b>2016</b> , 55, 626-39	63
1992	Immunotherapy for uveal melanoma. <b>2016</b> , 3, 125-135	3
1991	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. <b>2016</b> , 81, 219-226	4
1990	Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. <b>2016</b> , 138, 16686-16695	292

1989	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. <b>2016</b> , 4, 76	122
1988	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <b>2016</b> , 3, 11	96
1987	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. <b>2016</b> , 1,	74
1986	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. <b>2016</b> , 167, 1540-1554.e12	538
1985	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <b>2016</b> , 17, e542-e551	842
1984	Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices. <b>2016</b> , 103 Suppl 1, S151-S159	4
1983	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. <b>2016</b> , 11, 385-390	27
1982	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. <b>2016</b> , 4, 95	13
1981	Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy. <b>2016</b> , 36, 2625-2632	3
1980	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. <b>2016</b> , 8, 136	48
1979	Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. <b>2016</b> , 8, 1355-1361	14
1978	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. <b>2016</b> , 5, e109	22
1977	The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. <b>2016</b> , 9, 283-292	30
1976	T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy. <b>2016</b> , 5, e1249090	12
1975	T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. <b>2016</b> , 375, 2255-2262	681
1974	Molecular pathology of cancer: how to communicate with disease. <b>2016</b> , 1, e000085	15
1973	Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. <b>2016</b> , 22, 190-5	18
1972	Immuntherapien beim Mammakarzinom [Wie hängen Immunsystem und Krebs zusammen und woran arbeitet die Forschung?]. <b>2016</b> , 76, 503-506	

1971	mRNA Cancer Vaccines. <b>2016</b> , 209, 61-85	28
1970	Learning from the "tsunami" of immune checkpoint inhibitors in 2015. <b>2016</b> , 101, 213-20	30
1969	Disentangling the relationship between tumor genetic programs and immune responsiveness. <b>2016</b> , 39, 150-8	34
1968	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. <b>2016</b> , 5, e1165377	38
1967	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. <b>2016</b> , 34, 347-54	43
1966	A liquid biopsy for cancer immunotherapy. <b>2016</b> , 22, 340-1	15
1965	Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. <b>2016</b> , 4, 463-71	59
1964	Monitoring immune responses in the tumor microenvironment. <b>2016</b> , 41, 23-31	76
1963	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <b>2016</b> , 9, 47	221
1962	The promise of immunostimulatory antibodies in head and neck cancer. <b>2016</b> , 17, 856-857	7
1961	Targeting neoantigens for cancer immunotherapy. <b>2016</b> , 28, 365-70	37
1960	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. <b>2016</b> , 8, 681-6	1
1959	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <b>2016</b> , 22, 4585-93	655
1958	Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. <b>2016</b> , 115, 25-33	87
1957	Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. <b>2016</b> , 27, 1706-12	71
1956	IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists. <b>2016</b> , 197, 168-78	31
1955	The present status and future prospects of peptide-based cancer vaccines. <b>2016</b> , 28, 319-28	80
1954	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. <b>2016</b> , 17, 31	47



1953	PD-L1 Expression in Lung Cancer. <b>2016</b> , 11, 964-75	201
1952	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. <b>2016</b> , 65, 753-63	25
1951	Targeting T Cell Co-receptors for Cancer Therapy. <b>2016</b> , 44, 1069-78	314
1950	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <b>2016</b> , 22, 5487-5496	373
1949	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. <b>2016</b> , 29, 1104-12	153
1948	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. <i>Science</i> , <b>2016</b> , 352, 1337-41	295
1947	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. <b>2016</b> , 11, 313-41	12
1946	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. <b>2016</b> , 76, 3767-72	98
1945	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. <b>2016</b> , 8, 733-46	19
1944	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. <b>2016</b> , 37, 462-476	171
1943	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <b>2016</b> , 27, 1492-504	280
1942	Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. <b>2016</b> , 4, 592-9	38
1941	Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. <b>2016</b> , 11, 1282-1292	45
1940	The fourth modality: immunotherapy for head and neck cancer hits pay dirt. <b>2016</b> , 121, 575-7	3
1939	Understanding mutagenesis through delineation of mutational signatures in human cancer. <b>2016</b> , 37, 531-40	66
1938	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. <b>2016</b> , 21, 643-50	223
1937	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , <b>2016</b> , 352, 189-96	333 1961
1936	Les anticorps monoclonaux dirigés contre les checkpoints immunologiques : de nouvelles approches d'immunothérapie en onco-hématologie. <b>2016</b> , 4, 5-12	2

1935	Cripto-1 vaccination elicits protective immunity against metastatic melanoma. <b>2016</b> , 5, e1128613	18
1934	KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. <b>2016</b> , 25, 71-6	47
1933	Into the Clinic With Nivolumab and Pembrolizumab. <b>2016</b> , 21, 527-8	10
1932	Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. <b>2016</b> , 140, 245-8	9
1931	Cancer Immunotherapy Booster. <b>2016</b> , 165, 253-255	4
1930	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <b>2016</b> , 16, 275-87	1444
1929	The role of neoantigens in response to immune checkpoint blockade. <b>2016</b> , 28, 411-9	88
1928	Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?. <b>2016</b> , 22, 3422-4	28
1927	CCR9 in cancer: oncogenic role and therapeutic targeting. <b>2016</b> , 9, 10	39
1926	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. <b>2016</b> , 60, 26-39	25
1925	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. <b>2016</b> , 22, 1865-74	421
1924	Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. <b>2016</b> , 22, 1885-96	92
1923	Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. <b>2016</b> , 37, 8515-28	34
1922	Advances in immunotherapy for melanoma. <b>2016</b> , 14, 20	79
1921	T-Cell Epitope Discovery for Therapeutic Cancer Vaccines. <b>2016</b> , 1403, 779-96	11
1920	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <b>2016</b> , 12, 879-93	8
1919	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <b>2016</b> , 27, 1286-91	64
1918	Neoantigens and Microenvironment in Type 1 Diabetes: Lessons from Antitumor Immunity. <b>2016</b> , 27, 353-362	16

1917	Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. <b>2016</b> , 17, 350-361	83
1916	Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor. <b>2016</b> , 88, 50-8	11
1915	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. <b>2016</b> , 21, 634-42	274
1914	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <b>2016</b> , 374, 2542-52	828
1913	Reversing T-cell Dysfunction and Exhaustion in Cancer. <b>2016</b> , 22, 1856-64	216
1912	Immune checkpoint inhibition in ovarian cancer. <b>2016</b> , 28, 339-48	96
1911	Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. <b>2016</b> , 140, 341-4	98
1910	Nature Biotechnology's academic spinouts of 2015. <b>2016</b> , 34, 484-92	3
1909	Cancer immunotherapy: the beginning of the end of cancer?. <b>2016</b> , 14, 73	651
1908	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. <b>2016</b> , 22, 3127-31	66
1907	Mass spectrometry-based antigen discovery for cancer immunotherapy. <b>2016</b> , 41, 9-17	92
1906	Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem. <b>2016</b> , 37, 349-351	13
1905	Learning from PD-1 Resistance: New Combination Strategies. <b>2016</b> , 22, 448-451	52
1904	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <b>2016</b> , 48, 607-16	613
1903	Re-Evaluating Clonal Dominance in Cancer Evolution. <b>2016</b> , 2, 263-276	33
1902	Current tools for predicting cancer-specific T cell immunity. <b>2016</b> , 5, e1177691	31
1901	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <b>2016</b> , 12, 2219-31	33
1900	Recent developments in the use of immunotherapy in non-small cell lung cancer. <b>2016</b> , 10, 781-98	23

1899	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. <b>2016</b> , 6, 703-13	64
1898	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. <b>2016</b> , 4, 26	8
1897	Biomarkers associated with checkpoint inhibitors. <b>2016</b> , 27, 1199-206	112
1896	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <b>2016</b> , 28, 373-82	108
1895	What's hot in lung cancer. <b>2016</b> , 37, 79-85	
1894	Roles of regulatory T cells in cancer immunity. <b>2016</b> , 28, 401-9	280
1893	The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials. <b>2016</b> , 12, 2061-3	2
1892	Current Challenges in Cancer Treatment. <b>2016</b> , 38, 1551-66	318
1891	Clinical Implications of Genomic Discoveries in Lung Cancer. <b>2016</b> , 374, 1864-73	168
1890	The future of immunotherapy for sarcoma. <b>2016</b> , 16, 1049-57	19
1889	Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. <b>2016</b> , 28, 122-9	37
1888	Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. <b>2016</b> , 34, 2088-92	7
1887	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <b>2016</b> , 5, e1131379	73
1886	The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. <b>2016</b> , 12, 1833-46	13
1885	Perspectives for immunotherapy in endocrine cancer. <b>2016</b> , 23, R469-84	10
1884	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. <b>2016</b> , 4, 845-857	72
1883	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. <b>2016</b> , 4, 48	145
1882	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <b>2016</b> , 64, 587-600	24

1881	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. <b>2016</b> , 48, 1131-41	233
1880	Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. <b>2016</b> , 34, 3717-3718	10
1879	Genetics of triple-negative breast cancer: Implications for patient care. <b>2016</b> , 40, 130-140	17
1878	Biomarkers in Melanoma: Lessons from Translational Medicine. <b>2016</b> , 2, 305-312	6
1877	[Not Available]. <b>2016</b> , 103, S12-5	0
1876	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <b>2016</b> , 48, 1327-1329	84
1875	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <b>2016</b> , 4, 959-967	318
1874	Systemic chromosome instability in Shugoshin-1 mice resulted in compromised glutathione pathway, activation of Wnt signaling and defects in immune system in the lung. <b>2016</b> , 5, e256	10
1873	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. <b>2016</b> , 4, 936-947	82
1872	Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. <b>2016</b> , 6, 1230-1236	196
1871	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <b>2016</b> , 17, 2253-2266	22
1870	Proteogenomics. <b>2016</b> ,	
1869	Identification of Small Novel Coding Sequences, a Proteogenomics Endeavor. <b>2016</b> , 926, 49-64	13
1868	The genomic landscape of breast cancer and its interaction with host immunity. <b>2016</b> , 29, 241-50	130
1867	WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. <b>2016</b> , 243, 21-28	3
1866	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <b>2016</b> , 37, 771-782	8
1865	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. <b>2016</b> , 37, 760-770	33
1864	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <b>2016</b> , 22, 5642-5650	98

1863	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <b>2016</b> , 8, 79	109
1862	Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. <b>2016</b> , 113, E6409-E6417	111
1861	Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. <b>2016</b> , 5, e1238539	16
1860	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <b>2016</b> , 16, 1479-1489	10
1859	Genomic insights into head and neck cancer. <b>2016</b> , 1,	51
1858	Targeting Immune Checkpoints in Hematologic Malignancies. <b>2016</b> , 68, 1014-1025	26
1857	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. <b>2016</b> , 6, 1382-1399	356
1856	Local Radiation for Extensive Stage Small Cell Lung Cancer: A Step Forward or Running in Place?. <b>2016</b> , 17, 237-8	
1855	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <b>2016</b> , 99, 79-87	85
1854	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review. <b>2016</b> , 2, 1490-1495	53
1853	Metastatic melanoma and immunotherapy. <b>2016</b> , 172, 105-110	31
1852	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <b>2016</b> , 18, 59	28
1851	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <b>2016</b> , 61, 152-8	40
1850	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. <b>2016</b> , 21, 910-21	42
1849	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <b>2016</b> , 45, 389-401	318
1848	Socializing Individualized T-Cell Cancer Immunotherapy. <b>2016</b> , 24, 1170-3	1
1847	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. <b>2016</b> , 6,	204
1846	[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. <b>2016</b> , 37, 557-567	31

1845	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <b>2016</b> , 5, 2567-78	45
1844	Concepts in glioma immunotherapy. <b>2016</b> , 65, 1269-75	40
1843	MHC-multimer guided isolation of neoepitopes specific T cells as a potent-personalized cancer treatment strategy. <b>2016</b> , 5, e1159370	3
1842	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. <b>2016</b> , 5, 1481-91	58
1841	Precision medicine in pheochromocytoma and paraganglioma: current and future concepts. <b>2016</b> , 280, 559-573	36
1840	Immunotherapy for lung cancer. <b>2016</b> , 21, 821-33	126
1839	Translating cancer genomes and transcriptomes for precision oncology. <b>2016</b> , 66, 75-88	108
1838	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. <b>2016</b> , 36, 317-34	57
1837	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <b>2016</b> , 107, 107-15	22
1836	Gene aberrations for precision medicine against lung adenocarcinoma. <b>2016</b> , 107, 713-20	128
1835	Biomarkers in melanoma. <b>2016</b> , 245, S104-12	8
1834	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <b>2016</b> , 34, 794-796	14
1833	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. <b>2016</b> , 11, 1869-1878	66
1832	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. <b>2016</b> , 34, 1037-1045	176
1831	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. <b>2016</b> ,	1
1830	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <b>2016</b> , 11, 2066-2081	40
1829	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <b>2016</b> , 4, 820-822	44
1828	Cancer-Associated Tertiary Lymphoid Structures, from Basic Knowledge Toward Therapeutic Target in Clinic. <b>2016</b> , 99-125	

1827	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <b>2016</b> , 388, 1002-11	113
1826	Current Progress in Immunotherapy for the Treatment of Biliary Cancers. <b>2016</b> , 47, 351-357	8
1825	Precision medicine, genomics and drug discovery. <b>2016</b> , 25, R166-R172	35
1824	Congrès de l'Association américaine de recherche contre le cancer [AACR 2016]. <b>2016</b> , 18, 433-449	
1823	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <b>2016</b> , 11, 1387-96	6
1822	Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. <b>2016</b> , 140, 1243-1249	74
1821	Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody. <b>2016</b> , 28, 8912-8920	213
1820	Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ. <b>2016</b> , 197, 2509-21	20
1819	Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions. <b>2016</b> , 197, 2492-9	76
1818	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. <b>2016</b> , 34, 3562-3569	125
1817	Neoantigens encoded in the cancer genome. <b>2016</b> , 41, 98-103	54
1816	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <b>2016</b> , 122, 3354-3362	164
1815	In search of a target: PD-1 and PD-L1 profiling across glioma types. <b>2016</b> , 18, 1331-2	11
1814	Immunotherapy in Lung Cancer. <b>2016</b> , 170, 203-23	6
1813	Diagnosis and Molecular Classification of Lung Cancer. <b>2016</b> , 170, 25-46	84
1812	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. <b>2016</b> , 8, 360-74	33
1811	Stratified Treatment in Lung Cancer. <b>2016</b> , 39, 760-766	12
1810	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. <b>2016</b> , 34, 538-547	28



1809	Looking beyond the cancer cell for effective drug combinations. <b>2016</b> , 8, 125	24
1808	Direct identification of clinically relevant neopeptides presented on native human melanoma tissue by mass spectrometry. <b>2016</b> , 7, 13404	386
1807	High-content molecular profiling of T-cell therapy in oncology. <b>2016</b> , 3, 16009	5
1806	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. <b>2016</b> , 76, 6266-6277	57
1805	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. <b>2016</b> , 34, 3346-8	5
1804	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. <b>2016</b> , 9, 939-49	9
1803	Update in Lung Cancer 2015. <b>2016</b> , 194, 661-71	10
1802	Immunotherapy for prostate cancer: False promises or true hope?. <b>2016</b> , 122, 3598-3607	19
1801	Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions. <b>2016</b> , 11, 1602-3	2
1800	Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. <b>2016</b> , 61, 166-76	9
1799	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. <b>2016</b> , 21, 1200-1211	164
1798	Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. <b>2016</b> , 48, 1330-1338	104
1797	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. <b>2016</b> , 8, 460-473	26
1796	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. <b>2016</b> , 9, 89-104	113
1795	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. <b>2016</b> , 58, 7-14	99
1794	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <b>2016</b> , 37, 1004-12	5
1793	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. <b>2016</b> , 8, 775-84	19
1792	Personalized Immunotherapy Targeting the Cancer Mutanome. <b>2016</b> , 426-433	1

1791	Peptide vaccination therapy: Towards the next generation. <b>2016</b> , 66, 547-553	15
1790	Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine. <b>2016</b> , 25, R182-R189	18
1789	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. <b>2016</b> , 30, 397-405	31
1788	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. <b>2016</b> , 16, 1209-23	14
1787	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. <b>2016</b> , 1, e000022	13
1786	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <b>2016</b> , 7, 10582	248
1785	Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. <b>2016</b> , 1, e000081	5
1784	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <b>2016</b> , 17, 231	391
1783	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. <b>2016</b> , 6, 27702	38
1782	Tracking Cancer Genetic Evolution using OncoTrack. <b>2016</b> , 6, 29647	3
1781	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. <b>2016</b> , 113, E7769-E7777	116
1780	Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. <b>2016</b> , 34, 556-565	16
1779	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <b>2016</b> , 8, 328rv4	1281
1778	The Human Vaccines Project: A roadmap for cancer vaccine development. <b>2016</b> , 8, 334ps9	115
1777	Dendritic Cells and Cancer Immunity. <b>2016</b> , 37, 855-865	373
1776	Immunotherapy in Endometrial Cancer: In the Nick of Time. <b>2016</b> , 22, 5623-5625	18
1775	Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway. <b>2016</b> , 14, 295	
1774	Emerging role of checkpoint inhibition in localized bladder cancer. <b>2016</b> , 34, 548-555	14

1773	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <b>2016</b> , 14, 168	87
1772	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. <b>2016</b> , 8, 111	40
1771	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). <b>2016</b> , 18, 533-542	2
1770	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. <b>2016</b> , 7, 866-877	26
1769	PARP inhibitor combination therapy. <b>2016</b> , 108, 73-85	116
1768	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. <b>2016</b> , 21, 1450-1460	70
1767	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <b>2016</b> , 7, 12910	74
1766	Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. <b>2016</b> , 5, e1232237	29
1765	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. <b>2016</b> , 7, 13354	155
1764	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <b>2016</b> , 375, 1767-1778	661
1763	Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. <b>2016</b> , 6, 1210-1211	10
1762	Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. <b>2016</b> , 4, 1007-1015	58
1761	Era of cancer immunotherapy has come. <b>2016</b> , 39, 164-71	1
1760	Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. <b>2016</b> , 23, 61-6	12
1759	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <b>2016</b> , 2, 165-202	22
1758	Personalisierte Medizin: Strukturen, Tumorboards, Visionen. <b>2016</b> , 28, 452-459	1
1757	Neue Studienprodukte in der onkologischen Immuntherapie. <b>2016</b> , 31, 398-401	
1756	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <b>2016</b> , 14, 65	8

1755	Proceedings of the 2016 China Cancer Immunotherapy Workshop. <b>2016</b> , 9,	78
1754	Genomically personalized therapy in head and neck cancer. <b>2016</b> , 1, 2	18
1753	Cancer immunotherapy: new applications in urologic oncology. <b>2016</b> , 26, 535-42	9
1752	Cancer immunotherapy: new applications in urologic oncology. <b>2016</b> , 26, 556-63	4
1751	Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. <b>2016</b> , 175, 1382-1386	90
1750	Checkpoint inhibition in meningiomas. <b>2016</b> , 8, 721-31	18
1749	Progress in Cancer Immunotherapy. <b>2016</b> ,	5
1748	[Molecular and immunohistochemical diagnostics in melanoma]. <b>2016</b> , 67, 511-8	0
1747	Immunotherapy for small-cell lung cancer. <b>2016</b> , 17, 846-847	6
1746	Immunotherapy in Breast Cancer. <b>2016</b> , 39, 335-45	11
1745	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. <b>2016</b> , 9, 29	17
1744	Harnessing the antitumor immunity cycle to treat lung cancer. <b>2016</b> , 5, 40-48	
1743	Impact of genomic sequencing on precision medicine for clinical oncology. <b>2016</b> , 1, 255-265	
1742	RNA splicing factors as oncoproteins and tumour suppressors. <b>2016</b> , 16, 413-30	383
1741	Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology. <b>2016</b> , 4,	9
1740	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. <b>2016</b> , 4, 669-78	85
1739	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. <b>2016</b> , 29, 1028-37	62
1738	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. <b>2016</b> , 22, 3025-36	80

1737	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. <b>2016</b> , 17, 40	17
1736	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <b>2016</b> , 34, 469-76	7
1735	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <b>2016</b> , 4, 679-87	54
1734	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. <b>2016</b> , 44, 1255-69	554
1733	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <b>2016</b> , 13, 420-31	66
1732	Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference. <b>2016</b> , 4, 3-11	2
1731	Recent results of immunotherapy and perspectives for advanced NSCLC. <b>2016</b> , 5, 57-60	
1730	Mouse Models of Tumor Immunotherapy. <b>2016</b> , 130, 1-24	25
1729	Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma. <b>2016</b> , 17, 517-522.e3	16
1728	Neoantigen landscape dynamics during human melanoma-T cell interactions. <b>2016</b> , 536, 91-5	285
1727	Immunotherapy for gynecologic cancers. <b>2016</b> , 142, 3-5	9
1726	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. <b>2016</b> , 14, 589-98	20
1725	POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies. <b>2016</b> , 590, 128-41	68
1724	Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. <b>2016</b> , 12, 511-8	69
1723	Anaplastic Thyroid Carcinoma: Light at the End of the Tunnel?. <b>2016</b> , 12, 519-20	1
1722	Clinicopathologic Features of Advanced Squamous NSCLC. <b>2016</b> , 11, 1411-22	57
1721	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. <b>2016</b> , 11, 1819-1836	22
1720	Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. <b>2016</b> , 11, 1879-1890	118

1719	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. <b>2016</b> , 43, 501-13	8
1718	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. <b>2016</b> , 12, 1805-22	6
1717	Challenges & Perspectives of Immunotherapy Biomarkers & The HistoOncoImmuneMethodology. <b>2016</b> , 1, 9-24	4
1716	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. <b>2016</b> , 97, 73-80	96
1715	Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. <b>2016</b> , 58, 49-51	
1714	Translational and clinical implications of the genetic landscape of prostate cancer. <b>2016</b> , 13, 597-610	45
1713	Current and future immunotherapeutic approaches in Hodgkin lymphoma. <b>2016</b> , 57, 2014-24	16
1712	Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. <b>2016</b> , 12, 911-22	41
1711	Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. <b>2016</b> , 22, 3713-7	49
1710	Checkpoint Inhibitors and Their Application in Breast Cancer. <b>2016</b> , 11, 108-15	33
1709	Genomic determinants of cancer immunotherapy. <b>2016</b> , 41, 32-38	20
1708	Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. <b>2016</b> , 2, 445-452	56
1707	Novel Immunotherapeutic Approaches to the Treatment of Cancer. <b>2016</b> ,	1
1706	When Genome Maintenance Goes Badly Awry. <b>2016</b> , 62, 777-87	51
1705	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. <b>2016</b> , 57, 1607-1611	84
1704	Adoptive Cellular Therapy (ACT) for Cancer Treatment. <b>2016</b> , 909, 169-239	10
1703	"Pseudoprogression" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy. <b>2016</b> , 11, e117-9	26
1702	Personalized immunotherapy in colorectal cancer. <b>2016</b> , 1, 267-277	2

1701	The oncolytic virus <b>BK</b> has multimodal anti-tumor activity. <b>2016</b> , 74,	7
1700	Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?. <b>2016</b> , 11, 17	7
1699	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. <b>2016</b> , 2, 1217-22	165
1698	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <b>2016</b> , 6, 827-37	561
1697	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. <b>2016</b> , 1-39	
1696	Stratification in advanced non-small cell lung cancer: precision medicine in practice. <b>2016</b> , 1, 279-287	1
1695	Immunonkologische Therapiestrategien. <b>2016</b> , 11, 22-29	
1694	Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. <b>2016</b> , 194, 1403-1412	34
1693	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. <b>2016</b> , 166, 9-29	22
1692	Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. <b>2016</b> , 58, 127-35	51
1691	Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?. <b>2016</b> , 8, 763-6	7
1690	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. <b>2016</b> , 3, e1048929	24
1689	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. <b>2016</b> , 4, 3	146
1688	Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. <b>2016</b> , 11, 504-15	14
1687	Doubling the blockade for melanoma immunotherapy. <b>2016</b> , 5, e1106127	9
1686	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. <b>2016</b> , 37, 4251-61	62
1685	Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. <b>2016</b> , 11, 324-33	24
1684	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <b>2016</b> , 12, 551-64	7

1683	Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. <b>2016</b> , 13, 77-8	58
1682	A panoply of errors: polymerase proofreading domain mutations in cancer. <b>2016</b> , 16, 71-81	205
1681	Acquired resistance to immunotherapy and future challenges. <b>2016</b> , 16, 121-6	260
1680	Changing the course of pancreatic cancer--Focus on recent translational advances. <b>2016</b> , 44, 17-25	19
1679	Curing Metastatic Breast Cancer. <b>2016</b> , 12, 6-10	46
1678	Looking to the future in an unprecedented time for cancer drug development. <b>2016</b> , 43, 2-3	3
1677	Pembrolizumab for the treatment of non-small cell lung cancer. <b>2016</b> , 16, 397-406	52
1676	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. <b>2016</b> , 67, 73-89	212
1675	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. <b>2016</b> , 48, 177-87	141
1674	Cancer immune contexture and immunotherapy. <b>2016</b> , 39, 7-13	93
1673	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <b>2016</b> , 387, 1540-1550	3964
1672	Trial Watch-Immunostimulation with cytokines in cancer therapy. <b>2016</b> , 5, e1115942	35
1671	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <b>2016</b> , 13, 228-41	429
1670	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. <b>2016</b> , 76, 227-38	423
1669	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <b>2016</b> , 22, 2226-36	17
1668	Prime time for immune-checkpoint targeted therapy at ASCO 2015. <b>2016</b> , 5, e1068494	5
1667	Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. <b>2016</b> , 12, 9-23	11
1666	Immunomonitoring in glioma immunotherapy: current status and future perspectives. <b>2016</b> , 127, 1-13	15



1665	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <b>2016</b> , 5, e1100789	36
1664	Melanoma driver mutations and immune therapy. <b>2016</b> , 5, e1051299	8
1663	CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. <b>2016</b> , 39, 98-106	1102
1662	Cancer Immunosurveillance Caught in the Act. <b>2016</b> , 44, 525-526	4
1661	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <b>2016</b> , 22, 3915-23	73
1660	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <b>2016</b> , 165, 35-44	1552
1659	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <b>2016</b> , 2, 204-209	30
1658	Direct observation of proton pumping by a eukaryotic P-type ATPase. <i>Science</i> , <b>2016</b> , 351, 1469-73	33.3 57
1657	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. <b>2016</b> , 28, 383-91	146
1656	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <b>2016</b> , 34, 2206-11	537
1655	Unmasking targets of antitumor immunity via high-throughput antigen profiling. <b>2016</b> , 42, 92-97	9
1654	Scientific Advances in Lung Cancer 2015. <b>2016</b> , 11, 613-638	164
1653	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <b>2016</b> , 130, 25-74	119
1652	TCR-engineered T cells to treat tumors: Seeing but not touching?. <b>2016</b> , 28, 10-21	54
1651	Driving CAR T-cells forward. <b>2016</b> , 13, 370-83	362
1650	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. <b>2016</b> , 34, 1676-88	64
1649	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <b>2016</b> , 76, 999-1008	297
1648	Adoptive cell therapy: a highly successful individualized therapy for melanoma with great potential for other malignancies. <b>2016</b> , 39, 90-5	16

1647	The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8+ T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic Rabbits. <b>2016</b> , 90, 3913-3928	25
1646	Microsatellite Instability as a Biomarker for PD-1 Blockade. <b>2016</b> , 22, 813-20	470
1645	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. <b>2016</b> , 113, 2170-5	83
1644	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. <b>2016</b> , 22, 433-8	531
1643	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <b>2016</b> , 22, 3630-42	246
1642	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <b>2016</b> , 22, 2261-70	164
1641	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. <b>2016</b> , 44, 343-54	518
1640	Cancer vaccines: limited success but the research should remain viable. <b>2016</b> , 15, 677-80	4
1639	[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. <b>2016</b> , 36, 94-102	5
1638	Immunonkologische Therapiestrategien. <b>2016</b> , 22, 30-39	
1637	Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment. <b>2016</b> , 22, 122-4	15
1636	Immunotherapy and Oncogenic Pathways: The PTEN Connection. <b>2016</b> , 6, 128-9	16
1635	The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. <b>2016</b> , 196, 1480-7	106
1634	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. <b>2016</b> , 140, 326-31	99
1633	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. <b>2016</b> , 22, 3182-91	67
1632	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. <b>2016</b> , 22, 3618-29	242
1631	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. <b>2016</b> , 21, 462-73	190
1630	Leukaemia 'firsts' in cancer research and treatment. <b>2016</b> , 16, 163-72	46

1629	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. <b>2016</b> , 468, 511-25	172
1628	Coinhibitory Pathways in Immunotherapy for Cancer. <b>2016</b> , 34, 539-73	507
1627	[Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies]. <b>2016</b> , 103, 368-80	5
1626	Immunotherapy of Cancer. <b>2016</b> ,	2
1625	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <b>2016</b> , 11, 524-36	32
1624	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <b>2016</b> , 13, 273-90	640
1623	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <b>2016</b> , 18, 21	32
1622	Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. <b>2016</b> , 349-358	
1621	Targeting Oral Cancer. <b>2016</b> ,	
1620	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <b>2016</b> , 387, 1909-20	2308
1619	Immunotherapy in Head and Neck Cancers. <b>2016</b> , 211-224	
1618	Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. <b>2016</b> , 11, 976-88	161
1617	The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer. <b>2016</b> , 43, 3-10	4
1616	Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <b>2016</b> , 70, e75-6	
1615	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. <b>2016</b> , 13, 516-24	195
1614	The Basis of Oncoimmunology. <b>2016</b> , 164, 1233-1247	481
1613	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. <b>2016</b> , 22, 2102-4	26
1612	Vaccines for established cancer: overcoming the challenges posed by immune evasion. <b>2016</b> , 16, 219-33	449

1611	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , <b>2016</b> , 351, 1463-9	33.3	1758
1610	Advances in Therapeutic Cancer Vaccines. <b>2016</b> , 130, 191-249		71
1609	Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. <b>2016</b> , 16, 1-4		5
1608	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <b>2016</b> , 22, 793-801		43
1607	Beyond the exome: the role of non-coding somatic mutations in cancer. <b>2016</b> , 27, 240-8		24
1606	Cancer immunotherapy targeting neoantigens. <b>2016</b> , 28, 22-7		153
1605	Prospects for gene-engineered T cell immunotherapy for solid cancers. <b>2016</b> , 22, 26-36		243
1604	Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. <b>2016</b> , 22, 2734-43		56
1603	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. <b>2016</b> , 4, 204-14		115
1602	Tumor antigens in human cancer control. <b>2016</b> , 1865, 83-89		13
1601	Mutanome directed cancer immunotherapy. <b>2016</b> , 39, 14-22		44
1600	Immune suppressive mechanisms in the tumor microenvironment. <b>2016</b> , 39, 1-6		305
1599	PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. <b>2016</b> , 2, 15-6		84
1598	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. <b>2016</b> , 5, e1104448		38
1597	Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <b>2016</b> , 16, 131-3		46
1596	Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. <b>2016</b> , 16, 13-20		51
1595	Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. <b>2016</b> , 52, 1-9		91
1594	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <b>2016</b> , 22, 582-95		61

1593	Cancer Neoantigens and Applications for Immunotherapy. <b>2016</b> , 22, 807-12	146
1592	Immune checkpoint inhibitors: a new frontier in bladder cancer. <b>2016</b> , 34, 49-55	11
1591	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. <b>2016</b> , 49, 1324-33	26
1590	Novel immunotherapies in lymphoid malignancies. <b>2016</b> , 13, 25-40	172
1589	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. <b>2016</b> , 22, 1161-72	49
1588	CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy. <b>2016</b> , 12, 213-21	1
1587	Tumor-intrinsic oncogene pathways mediating immune avoidance. <b>2016</b> , 5, e1086862	81
1586	The Immunotherapy Roadmap. <b>2016</b> , 22, 275-6	2
1585	From T cell "exhaustion" to anti-cancer immunity. <b>2016</b> , 1865, 49-57	13
1584	Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration. <b>2016</b> , 2, 118-22	41
1583	Personalized approaches to active immunotherapy in cancer. <b>2016</b> , 1865, 72-82	30
1582	Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. <b>2016</b> , 17, 642-56	83
1581	Decision support systems for personalized and participative radiation oncology. <b>2017</b> , 109, 131-153	79
1580	Integrating chemoradiation and molecularly targeted therapy. <b>2017</b> , 109, 74-83	14
1579	Advances in personalized cancer immunotherapy. <b>2017</b> , 24, 16-24	55
1578	Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer. <b>2017</b> , 107, 50-58	34
1577	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. <b>2017</b> , 17, 528-534	7
1576	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <b>2017</b> , 14, 115-128	62

1575	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. <b>2017</b> , 7,	16
1574	Elements of cancer immunity and the cancer-immune set point. <b>2017</b> , 541, 321-330	2136
1573	Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. <i>Science</i> , <b>2017</b> , 355,	33-3 609
1572	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. <b>2017</b> , 103, e123-e125	4
1571	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. <b>2017</b> , 4, 72-75	
1570	High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. <b>2017</b> , 104, 1-6	110
1569	Molecular chess? Hallmarks of anti-cancer drug resistance. <b>2017</b> , 17, 10	140
1568	Immunotherapy and patients treated for cancer with microsatellite instability. <b>2017</b> , 104, 42-51	45
1567	Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. <b>2017</b> , 15, e521-e524	12
1566	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <b>2017</b> , 110, 106-116	29
1565	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <b>2017</b> , 53, 138-145	15
1564	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <b>2017</b> , 53, 79-97	64
1563	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. <b>2017</b> , 18, 212-220	246
1562	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. <b>2017</b> , 29, 207-217	5
1561	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. <b>2017</b> , 309-327	1
1560	Neutrophils dominate the immune cell composition in non-small cell lung cancer. <b>2017</b> , 8, 14381	190
1559	The Antigenicity of the Tumor Cell - Context Matters. <b>2017</b> , 376, 491-493	16
1558	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. <b>2017</b> , 6, e1279777	40

1557	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <b>2017</b> , 23, 3610-3618	143
1556	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <b>2017</b> , 18, 295-304	10
1555	PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?. <b>2017</b> , 12, 171-172	4
1554	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. <b>2017</b> , 15, 1	116
1553	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <b>2017</b> , 5, 106-117	162
1552	Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model. <b>2017</b> , 66, 491-502	6
1551	Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. <b>2017</b> , 331, 1-53	30
1550	MHC class II restricted neoantigen: A promising target in tumor immunotherapy. <b>2017</b> , 392, 17-25	39
1549	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. <b>2017</b> , 12, 791-803	85
1548	Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. <b>2017</b> , 6, e1278330	45
1547	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. <b>2017</b> , 15, 17	31
1546	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <b>2017</b> , 18, 323-335	133
1545	Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. <b>2017</b> , 77, 1271-1282	83
1544	Targeting ALK: Precision Medicine Takes on Drug Resistance. <b>2017</b> , 7, 137-155	269
1543	[Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma]. <b>2017</b> , 37, 55-60	1
1542	[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. <b>2017</b> , 37, 46-54	1
1541	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <b>2017</b> , 6, e1286437	21
1540	Developing immunotherapies for childhood cancer. <b>2017</b> , 102, 162-165	1

1539	Emerging role of checkpoint blockade therapy in lymphoma. <b>2017</b> , 8, 81-90	20
1538	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <b>2017</b> , 46, 197-204	288
1537	Targeting neoantigens to augment antitumour immunity. <b>2017</b> , 17, 209-222	449
1536	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. <b>2017</b> , 18, 303-310	10
1535	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. <b>2017</b> , 5, 1	37
1534	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <b>2017</b> , 23, 3168-3180	51
1533	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <b>2017</b> , 24, R123-R144	45
1532	[Immune response and digestive cancers: Prognostic and therapeutic implications]. <b>2017</b> , 37, 111-116	1
1531	[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. <b>2017</b> , 37, 61-78	10
1530	PD-1 and PD-L1 antibodies in cancer: current status and future directions. <b>2017</b> , 66, 551-564	188
1529	Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing. <b>2017</b> , 108, 170-177	39
1528	CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations. <b>2017</b> , 77, 1918-1926	19
1527	[Current events in immunotherapy for upper aerodigestive tract cancer]. <b>2017</b> , 37, 79-89	7
1526	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. <b>2017</b> , 67, 61-69	35
1525	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <b>2017</b> , 23, 4416-4428	174
1524	Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?. <b>2017</b> , 130, e207-e208	7
1523	Precision medicine driven by cancer systems biology. <b>2017</b> , 36, 91-108	30
1522	Towards a better cancer precision medicine: systems biology meets immunotherapy. <b>2017</b> , 2, 67-73	5



1521	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. <b>2017</b> , 55, 83-95	48
1520	Immune checkpoint inhibitors in challenging populations. <b>2017</b> , 123, 1904-1911	194
1519	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. <b>2017</b> , 77, 2464-2475	71
1518	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. <b>2017</b> , 92, 283-290	31
1517	Combination immunotherapy: a road map. <b>2017</b> , 5, 16	228
1516	Candidate immune biomarkers for radioimmunotherapy. <b>2017</b> , 1868, 58-68	13
1515	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <b>2017</b> , 9,	409
1514	EGFR inhibition in NSCLC: New findings and opened questions?. <b>2017</b> , 112, 126-135	20
1513	A comprehensive review of immunotherapies in prostate cancer. <b>2017</b> , 113, 292-303	43
1512	JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. <b>2017</b> , 7, 128-130	15
1511	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <b>2017</b> , 6, e1253654	87
1510	Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. <b>2017</b> , 15, 5	23
1509	PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer. <b>2017</b> , 115-146	
1508	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <b>2017</b> , 116, 802-810	93
1507	High expression of PD-1 ligands is associated with mutational signature and APOBEC3 alterations. <b>2017</b> , 6, e1284719	42
1506	Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer. <b>2017</b> , 6, 7	27
1505	Applications of Immunogenomics to Cancer. <b>2017</b> , 168, 600-612	129
1504	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. <b>2017</b> , 168, 707-723	2141

1503	Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. <b>2017</b> , 168, 613-628	1185
1502	Designing nanomedicine for immuno-oncology. <b>2017</b> , 1,	138
1501	Tissue-specific tumorigenesis: context matters. <b>2017</b> , 17, 239-253	160
1500	The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. <b>2017</b> , 12, 850-859	64
1499	The CD47-SIRP $\alpha$ signaling axis as an innate immune checkpoint in cancer. <b>2017</b> , 276, 145-164	225
1498	Biological therapies in nonsmall cell lung cancer. <b>2017</b> , 49,	29
1497	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <b>2017</b> , 14, 1049-1065	15
1496	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <b>2017</b> , 72, 962-971	136
1495	Immunoregulatory functions of VISTA. <b>2017</b> , 276, 66-79	104
1494	Hypermutated Colorectal Cancer and Neoantigen Load. <b>2017</b> , 187-215	2
1493	Debugging the Black Box. <b>2017</b> , 7, 250-251	
1492	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. <b>2017</b> , 18, 572-582.e1	39
1491	The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. <b>2017</b> , 111, 124-132	67
1490	Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. <b>2017</b> , 44, 3-7	63
1489	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. <b>2017</b> , 18, 255-262	260
1488	The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. <b>2017</b> , 24, 89-99	18
1487	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <b>2017</b> , 545, 60-65	850
1486	Resistance to immunotherapy: clouds in a bright sky. <b>2017</b> , 35, 649-654	8

1485	Targeting the immune system in glioblastoma. <b>2017</b> , 2, 121-131	
1484	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. <i>Science</i> , <b>2017</b> , 356, 200-205	33.3 231
1483	Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. <b>2017</b> , 66, 927-939	52
1482	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. <b>2017</b> , 78, 16-23	75
1481	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. <b>2017</b> , 145, 420-425	42
1480	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <b>2017</b> , 129, 3419-3427	244
1479	MuPeXI: prediction of neo-epitopes from tumor sequencing data. <b>2017</b> , 66, 1123-1130	95
1478	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <b>2017</b> , 22, 690-697	17
1477	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <b>2017</b> , 9, 34	1509
1476	Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. <b>2017</b> , 28, 1532-1539 <sup>167</sup>	
1475	Kleinzelliges Lungenkarzinom. <b>2017</b> , 23, 340-346	
1474	Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. <b>2017</b> , 23, 131-137	7
1473	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <b>2017</b> , 5, 417-424	241
1472	Wnt Signaling and Colorectal Cancer. <b>2017</b> , 13, 101-110	122
1471	WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. <b>2017</b> ,	
1470	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <b>2017</b> , 23, 115-124	7
1469	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <b>2017</b> , 72, 557-564	81
1468	Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma. <b>2017</b> , 23, 125-130	15

1467	Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer. <b>2017</b> , 41, 2045-2052	12
1466	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <b>2017</b> , 28, 874-881	144
1465	Immune checkpoint inhibitors in lung cancer: an update. <b>2017</b> , 13, 955-959	4
1464	Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8 T cells. <b>2017</b> , 6, e1318234	7
1463	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. <b>2017</b> , 38, 513-525	58
1462	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <b>2017</b> , 133, 561-569	35
1461	Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance. <b>2017</b> , 37, 1989-1997	6
1460	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. <b>2017</b> , 102, 1943-1950	54
1459	Use of precision methods to accelerate drug development in oncology. <b>2017</b> , 2, 109-120	
1458	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. <b>2017</b> , 12, 1268-1279	99
1457	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <b>2017</b> , 9, 507-520	8
1456	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. <b>2017</b> , 429, 1767-1786	12
1455	In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. <b>2017</b> , 9,	331
1454	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <b>2017</b> , 77, 3540-3550	213
1453	Checkpoint inhibitors in hematological malignancies. <b>2017</b> , 10, 103	79
1452	Personalized T cell-mediated cancer immunotherapy: progress and challenges. <b>2017</b> , 48, 142-152	68
1451	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. <b>2017</b> , 6, e1320626	47
1450	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <b>2017</b> , 195, 1150-1160	57

1449	Human Tumor Antigens Yesterday, Today, and Tomorrow. <b>2017</b> , 5, 347-354	55
1448	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. <b>2017</b> , 11, 469-479	9
1447	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. <b>2017</b> , 56, 651-659	30
1446	CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8 T and CD8 T Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease. <b>2017</b> , 91,	27
1445	Characterizing neoantigens for personalized cancer immunotherapy. <b>2017</b> , 46, 58-65	40
1444	A novel molecular diagnostics platform for somatic and germline precision oncology. <b>2017</b> , 5, 336-359	10
1443	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <b>2017</b> , 114, 4993-4998	375
1442	Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. <b>2017</b> , 35, 229-253	74
1441	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. <b>2017</b> , 77, 3666-3671	47
1440	Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration. <b>2017</b> , 2, 103-114	29
1439	Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. <b>2017</b> , 23, 138-143	24
1438	Immunotherapy in Lung Cancer. <b>2017</b> , 31, 131-141	26
1437	Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. <b>2017</b> , 31, 1695-1705	69
1436	Lung Cancer Biomarkers. <b>2017</b> , 31, 13-29	104
1435	Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions. <b>2017</b> , 31, 1-12	10
1434	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. <b>2017</b> , 7, 188-201	692
1433	The Immune Response to Implanted Materials and Devices. <b>2017</b> ,	14
1432	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <b>2017</b> , 18, 31-41	605

1431	Resistance to PD1/PDL1 checkpoint inhibition. <b>2017</b> , 52, 71-81	305
1430	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. <b>2017</b> , 93, 1-14	6
1429	Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. <b>2017</b> , 56, 16-25	51
1428	DNA repair and systemic lupus erythematosus. <b>2017</b> , 56, 174-182	12
1427	Breast Cancer Neoantigens Can Induce CD8 T-Cell Responses and Antitumor Immunity. <b>2017</b> , 5, 516-523	40
1426	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <b>2017</b> , 143, 1977-1984	11
1425	More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer. <b>2017</b> , 28, 685-687	1
1424	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <b>2017</b> , 12, 563-569	50
1423	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. <b>2017</b> , 19, 45	58
1422	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <b>2017</b> , 545, 452-456	413
1421	Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing. <b>2017</b> , 14, 189-192	
1420	The Promise and the Hype of 'Personalised Medicine'. <b>2017</b> , 23, 13-20	24
1419	Immune Signatures of Non-Small Cell Lung Cancer. <b>2017</b> , 12, 913-915	4
1418	Therapeutic Vaccine of Gastric Cancer. <b>2017</b> , 131-147	
1417	Immunogenomics: using genomics to personalize cancer immunotherapy. <b>2017</b> , 471, 209-219	5
1416	Hallmarks of response to immune checkpoint blockade. <b>2017</b> , 117, 1-7	138
1415	Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. <b>2017</b> , 28, 748-753	37
1414	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <b>2017</b> , 376, 2415-2426	1474

1413	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. <b>2017</b> , 6, e1339856	6
1412	The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. <b>2017</b> , 6, e1338996	15
1411	DNA Damage and Repair Biomarkers of Immunotherapy Response. <b>2017</b> , 7, 675-693	331
1410	Immunotherapy: The Wave of the Future in Bladder Cancer?. <b>2017</b> , 15, S3-S17	6
1409	Recent progress in immunotherapy for urological cancer. <b>2017</b> , 24, 735-742	12
1408	Immunotherapy for Breast Cancer: What Are We Missing?. <b>2017</b> , 23, 2640-2646	112
1407	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <b>2017</b> , 58, 22-33	51
1406	Treatment advances in small cell lung cancer (SCLC). <b>2017</b> , 180, 16-23	94
1405	Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. <b>2017</b> , 25, 1917-1932	37
1404	A molecular portrait of microsatellite instability across multiple cancers. <b>2017</b> , 8, 15180	288
1403	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , <b>2017</b> , 357, 409-413	3274
1402	Precision medicine for hepatocellular carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. <b>2017</b> , 8, e2867	7
1401	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. <b>2017</b> , 5, 23	87
1400	A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. <b>2017</b> , 14, 737-742	62
1399	Unravelling the biology of SCLC: implications for therapy. <b>2017</b> , 14, 549-561	209
1398	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. <b>2017</b> , 18, 36	14
1397	Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). <b>2017</b> , 12, 6-13	8
1396	Therapeutic T cell engineering. <b>2017</b> , 545, 423-431	420

1395	Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. <b>2017</b> , 33, 126-132	1
1394	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. <b>2017</b> , 110, 26-31	44
1393	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <b>2017</b> , 70, 34-42	29
1392	Interaction of molecular alterations with immune response in melanoma. <b>2017</b> , 123, 2130-2142	18
1391	Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. <b>2017</b> , 14, 309-325	16
1390	Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a Mutation. <b>2017</b> , 15, 142-147	132
1389	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <b>2017</b> , 16, 1705-1717	36
1388	Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. <b>2017</b> , 22, 631-637	60
1387	Genomic landscape of high-grade meningiomas. <b>2017</b> , 2,	78
1386	Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models. <b>2017</b> , 7, 2396	55
1385	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <b>2017</b> , 18, 719-723	10
1384	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. <b>2017</b> , 3,	16
1383	Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis. <b>2017</b> , 994, 105-118	2
1382	Immunotherapy and radiation in glioblastoma. <b>2017</b> , 134, 531-539	25
1381	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. <b>2017</b> , 19, 1874-1887	74
1380	Scientific Advances in Thoracic Oncology 2016. <b>2017</b> , 12, 1183-1209	29
1379	DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. <b>2017</b> , 49, 1052-1060	157
1378	Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. <b>2017</b> , 123, 3807-3815	99



1377	Resistance primaire et resistance acquise aux inhibiteurs PD-1. <b>2017</b> , 19, 243-245	
1376	Glioblastoma targeted therapy: updated approaches from recent biological insights. <b>2017</b> , 28, 1457-1472	230
1375	CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens. <b>2017</b> , 33, 3110-3112	37
1374	Analytic inquiry: Molecular testing in lung cancer. <b>2017</b> , 125, 470-476	11
1373	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. <b>2017</b> , 6, e1313371	7
1372	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. <b>2017</b> , 23, 6002-6011	21
1371	New insights into the role of EMT in tumor immune escape. <b>2017</b> , 11, 824-846	180
1370	Metastatic melanoma moves on: translational science in the era of personalized medicine. <b>2017</b> , 36, 7-21	15
1369	Immunotherapy for Esophageal Squamous Cell Carcinoma. <b>2017</b> , 19, 33	35
1368	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <b>2017</b> , 18, 599-610	215
1367	Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma. <b>2017</b> , 153, 249-262.e2	72
1366	Data resources for the identification and interpretation of actionable mutations by clinicians. <b>2017</b> , 28, 946-957	18
1365	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. <b>2017</b> , 19, 1047-1057	215
1364	[Brain tumor immunotherapy: Illusion or hope?]. <b>2017</b> , 104, 476-484	
1363	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <b>2017</b> , 18, 559-564	8
1362	Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation. <b>2017</b> , 2, 29-35	25
1361	The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. <b>2017</b> , 3, 584-589	10
1360	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. <b>2017</b> , 46, 210-219	71

1359	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <b>2017</b> , 7, 596-609	317
1358	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <b>2017</b> , 15, 55	43
1357	Overview of Basic Immunology for Clinical Investigators. <b>2017</b> , 995, 1-31	4
1356	Systematic evaluation of immune regulation and modulation. <b>2017</b> , 5, 21	15
1355	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. <b>2017</b> , 66, 865-876	94
1354	Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. <b>2017</b> , 6, e1306617	3
1353	Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. <b>2017</b> , 39, e183-e186	11
1352	Masterful Antibodies: Checkpoint Blockade. <b>2017</b> , 5, 275-281	25
1351	Cancer immunotherapies targeting the PD-1 signaling pathway. <b>2017</b> , 24, 26	332
1350	Biomarkers to predict prognosis and response to checkpoint inhibitors. <b>2017</b> , 22, 629-634	39
1349	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. <b>2017</b> , 28, 1036-1041	138
1348	Tumor Vaccines for Malignant Gliomas. <b>2017</b> , 14, 345-357	32
1347	Connecting the Metabolic and Immune Responses to Cancer. <b>2017</b> , 23, 451-464	43
1346	High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. <b>2017</b> , 141, 184-190	4
1345	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. <b>2017</b> , 108, 205-211	22
1344	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. <b>2017</b> , 34, 331-357	6
1343	Cancer Immunotherapy: Whence and Whither. <b>2017</b> , 15, 635-650	24
1342	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <b>2017</b> , 31, 476-485	86

1341	Chimeric antigen receptor T cells: a novel therapy for solid tumors. <b>2017</b> , 10, 78	179
1340	Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?. <b>2017</b> , 58, 2523-2531	3
1339	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <b>2017</b> , 27, 3991-4001	65
1338	Immunomodulating and Immuno-resistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. <b>2017</b> , 46, 221-238	59
1337	Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer. <b>2017</b> , 12, 431-447	9
1336	Hepatic IFIT3 predicts interferon- $\gamma$ therapeutic response in patients of hepatocellular carcinoma. <b>2017</b> , 66, 152-166	38
1335	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <b>2017</b> , 132, 359-372	7
1334	[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma]. <b>2017</b> , 58, 409-423	1
1333	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. <b>2017</b> , 178, 31-47	58
1332	Biomarkers and Immunotherapeutic Targets in Glioblastoma. <b>2017</b> , 102, 494-506	19
1331	NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. <b>2017</b> , 11, 438-451	73
1330	Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?. <b>2017</b> , 72, 972-973	
1329	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. <b>2017</b> , 12, 932-942	85
1328	Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy. <b>2017</b> , 1, 447-466	21
1327	Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. <b>2017</b> , 45, 82-88	17
1326	Immunotherapy. <b>2017</b> ,	4
1325	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. <b>2017</b> , 27, 289-298	28
1324	Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. <b>2017</b> , 5, 376-384	63

1323	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. <b>2017</b> , 5, 12	121
1322	Evolution of MHC-based technologies used for detection of antigen-responsive T cells. <b>2017</b> , 66, 657-666	46
1321	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. <b>2017</b> , 12, 943-953	88
1320	Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. <b>2017</b> , 543, 723-727	161
1319	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. <b>2017</b> , 140, 2535-2544	30
1318	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <b>2017</b> , 389, 67-76	1171
1317	A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. <b>2017</b> , 28, 798-803	31
1316	Genomic pathobiology of gastric carcinoma. <b>2017</b> , 67, 63-71	8
1315	Immuno-Oncology: The Third Paradigm in Early Drug Development. <b>2017</b> , 12, 125-138	16
1314	Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. <b>2017</b> , 23, 3129-3138	127
1313	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. <b>2017</b> , 103, 44-51	56
1312	Immune targets and neoantigens for cancer immunotherapy and precision medicine. <b>2017</b> , 27, 11-37	139
1311	Dendritic cell-based immunotherapy. <b>2017</b> , 27, 74-95	328
1310	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. <b>2017</b> , 66, 441-449	22
1309	Molecular approaches for classifying endometrial carcinoma. <b>2017</b> , 145, 200-207	88
1308	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <b>2017</b> , 7, 264-276	491
1307	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. <b>2017</b> , 144, 96-100	12
1306	Immunotherapy for Gastrointestinal Cancer. <b>2017</b> ,	0

1305	Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer. <b>2017</b> , 49, 120-132	13
1304	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). <b>2017</b> , 18, 333-339	32
1303	T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. <b>2017</b> , 38, 104-115	64
1302	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. <b>2017</b> , 6, e1260214	5
1301	Building proteomic tool boxes to monitor MHC class I and class II peptides. <b>2017</b> , 17, 1600061	20
1300	Patient-Derived Xenografts in Oncology. <b>2017</b> , 13-40	
1299	Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs. <b>2017</b> , 18, 401-409	8
1298	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. <b>2017</b> , 12, 75-102	19
1297	Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. <b>2017</b> , 23, 3012-3024	442
1296	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. <b>2017</b> , 35, 243-252	15
1295	Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. <b>2017</b> , 18, 248-262	1179
1294	DNA sequencing technologies: 2006-2016. <b>2017</b> , 12, 213-218	181
1293	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <b>2017</b> , 16, 264-272	127
1292	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <b>2017</b> , 6, e1264565	79
1291	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. <b>2017</b> , 1499, 223-236	7
1290	PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. <b>2017</b> , 103, 52-57	21
1289	Looking beyond drivers and passengers in cancer genome sequencing data. <b>2017</b> , 28, 938-945	22
1288	Emerging biomarkers for PD-1 pathway cancer therapy. <b>2017</b> , 11, 53-67	9

1287	DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes. <b>2017</b> , 26, 328-338	40
1286	A new molecular paradigm in mycosis fungoides and Sézary syndrome. <b>2017</b> , 34, 15-21	19
1285	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <b>2017</b> , 5, 84-91	70
1284	RNA Vaccines. <b>2017</b> ,	3
1283	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer. <b>2017</b> , 77, 851-861	35
1282	MHC-I Genotype Restricts the Oncogenic Mutational Landscape. <b>2017</b> , 171, 1272-1283.e15	180
1281	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <b>2017</b> , 171, 1259-1271.e11	541
1280	DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. <b>2017</b> , 15, 1063-1069	19
1279	T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. <b>2017</b> , 5, 978-991	97
1278	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. <b>2017</b> , 38, 1041-1051	10
1277	Small-cell lung cancer: what we know, what we need to know and the path forward. <b>2017</b> , 17, 725-737	286
1276	[Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges]. <b>2017</b> , 142, 1676-1684	4
1275	[Personalized therapy of lung cancer - current standard and future challenges]. <b>2017</b> , 142, 1660-1668	0
1274	Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. <b>2017</b> , 22, 1444-1450	50
1273	Sepsis: Staging and Potential Future Therapies. <b>2017</b> , 9, i-91	
1272	Future cancer research priorities in the USA: a Lancet Oncology Commission. <b>2017</b> , 18, e653-e706	106
1271	Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. <b>2017</b> , 113, 93-101	21
1270	Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. <b>2017</b> , 73, 65-69	28

1269	Doubling Down on BRCA-Mutated Cancer. <b>2017</b> , 3, 743-744	2
1268	[The Significance of Surgery for Oligometastatic and Oligoprogressive Non-small Cell Lung Cancer]. <b>2017</b> , 142, S38-S43	1
1267	Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer. <b>2017</b> , 23, 7596-7607	9
1266	PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung. <b>2017</b> , 51, 357-362	28
1265	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. <b>2017</b> , 2, e000236	19
1264	Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. <b>2017</b> , 23, 5729-5736	133
1263	Radiomics: the bridge between medical imaging and personalized medicine. <b>2017</b> , 14, 749-762	1576
1262	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <b>2017</b> , 29, 1703969	260
1261	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <b>2017</b> , 8, 1197	46
1260	Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation. <b>2017</b> , 40, 691-696	2
1259	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. <b>2017</b> , 6, e1386829	143
1258	An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. <b>2017</b> , 9,	108
1257	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. <b>2017</b> , 32, 506-519.e5	146
1256	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <b>2017</b> , 47, 1584-1797	359
1255	Determining T-cell specificity to understand and treat disease. <b>2017</b> , 1, 784-795	8
1254	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. <b>2017</b> , 77, 6119-6130	56
1253	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <b>2017</b> , 119, 30-39	29
1252	Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. <b>2017</b> , 86, 15-27	44

1251	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <b>2017</b> , 7, 1420-1435	302
1250	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <b>2017</b> , 171, 934-949.e16	831
1249	ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer. <b>2017</b> , 39, 1010428317734816	10
1248	Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. <b>2017</b> , 280, 231-248	88
1247	FEATURES. <b>2017</b> , 21, 14-27	
1246	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <b>2017</b> , 3, e173290	152
1245	Comprehensive Analysis of Hypermutation in Human Cancer. <b>2017</b> , 171, 1042-1056.e10	417
1244	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <b>2017</b> , 8, 1050	75
1243	Mechanisms regulating T-cell infiltration and activity in solid tumors. <b>2017</b> , 28, xii18-xii32	175
1242	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. <b>2017</b> , 123, 3628-3637	30
1241	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. <b>2017</b> , 148, 441-449	11
1240	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. <b>2017</b> , 28, 3015-3021	52
1239	Avelumab and other recent advances in Merkel cell carcinoma. <b>2017</b> , 13, 2771-2783	9
1238	Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. <b>2017</b> , 7, 13902	12
1237	Checkpoint immunotherapy in head and neck cancers. <b>2017</b> , 36, 475-489	27
1236	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <b>2017</b> , 170, 927-938.e20	267
1235	Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy. <b>2017</b> , 3, 726-741	16
1234	Evolutionary biology of high-risk multiple myeloma. <b>2017</b> , 17, 543-556	119



1233	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <b>2017</b> , 16, 2598-2608	1183
1232	Nucleotide Excision Repair: From Neurodegeneration to Cancer. <b>2017</b> , 1007, 17-39	15
1231	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. <b>2017</b> , 77, 1645-1655	4
1230	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. <b>2017</b> , 18, 1477-1490	16
1229	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. <b>2017</b> , 11, 353-373	19
1228	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. <b>2017</b> , 12, 484-494	3
1227	Optimizing tumor immune response through combination of radiation and immunotherapy. <b>2017</b> , 34, 165	8
1226	CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy. <b>2017</b> , 13, 2272-2279	
1225	PDL-1/PD1 inhibitors: antibody or antinobody?. <b>2017</b> , 13, 1669-1671	7
1224	Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. <b>2017</b> , 15, 1722-1732	70
1223	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. <b>2017</b> , 12, 709-718	13
1222	Trial watch: Immune checkpoint blockers for cancer therapy. <b>2017</b> , 6, e1373237	53
1221	Greener revolutions for all require transparency and diversity, not secrecy. <b>2017</b> , 35, 817-818	1
1220	Classifying the evolutionary and ecological features of neoplasms. <b>2017</b> , 17, 605-619	208
1219	Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8 T cells. <b>2017</b> , 8, 562	67
1218	Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer. <b>2017</b> , 23, 5394-5405	48
1217	Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission. <b>2017</b> , 24, T311-T329	15
1216	Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. <b>2017</b> , 22, 1478-1490	126

1215	Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. <b>2017</b> , 6, 2347-2356	35
1214	Mitochondrial Metabolism: Yin and Yang for Tumor Progression. <b>2017</b> , 28, 748-757	41
1213	Zukünftige Entwicklungen in der Immunonkologie. <b>2017</b> , 20, 65-72	
1212	[Progress in cancer immunotherapy]. <b>2017</b> , 159, 48-53	
1211	Targeting Immune Checkpoints in Cancer Therapy. <b>2017</b> , 318, 1647-1648	83
1210	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <b>2017</b> , 410, 3-27	36
1209	Checking in: T cells against multiple myeloma. <b>2017</b> , 130, 1175-1176	3
1208	Neoantigen prediction and the need for validation. <b>2017</b> , 35, 815-817	48
1207	Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. <b>2017</b> , 7, 7848	35
1206	Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. <b>2017</b> , 113, 106-114	33
1205	Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. <b>2017</b> , 77, 4755-4762	59
1204	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <b>2017</b> , 7, 1394-1403	384
1203	Using PDX for Biomarker Development. <b>2017</b> , 127-140	1
1202	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <b>2017</b> , 23, 4970-4979	54
1201	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. <b>2017</b> , 23, 4980-4991 <sup>12</sup>	
1200	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <b>2017</b> , 23, 4959-4969	71
1199	Atezolizumab for the treatment of non-small cell lung cancer. <b>2017</b> , 10, 935-945	21
1198	A perspective on the impact of radiation therapy on the immune rheostat. <b>2017</b> , 90, 20170272	6

1197	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <b>2017</b> , 18, 1261-1273	266
1196	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. <b>2017</b> , 6, e1338997	22
1195	CD1d-dependent CLL progression?. <b>2017</b> , 129, 3398-3399	
1194	Oncolytic virus-induced cell death and immunity: a match made in heaven?. <b>2017</b> , 102, 631-643	27
1193	Cancer Immunotherapy in Older Patients. <b>2017</b> , 23, 219-222	14
1192	Lung cancer as a paradigm for precision oncology in solid tumours. <b>2017</b> , 471, 221-233	10
1191	The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. <b>2017</b> , 187, 2185-2198	9
1190	HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients. <b>2017</b> , 137, 2443-2444	8
1189	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <b>2017</b> , 80, 591-598	34
1188	Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. <b>2017</b> , 31, 56-61	12
1187	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. <b>2017</b> , 97, 1063-1071	105
1186	The immune contexture in cancer prognosis and treatment. <b>2017</b> , 14, 717-734	935
1185	A novel method to quantify base substitution mutations at the 10 per bp level in DNA samples. <b>2017</b> , 403, 152-158	6
1184	Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. <b>2017</b> , 15, e897-e901	12
1183	Clinicopathologic significance of epithelio-mesenchymal transition in human lung adenocarcinomas: An integrative analysis, inclusive of genetic alterations, on 256 surgically resected cases. <b>2017</b> , 12, 62-68	2
1182	Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study. <b>2017</b> , 124, 157-164	7
1181	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. <b>2017</b> , 6, e1356145	177
1180	Oesophageal cancer. <b>2017</b> , 3, 17048	367

1179	Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way. <b>2017</b> , 18, 1299-1304	4
1178	A step towards predicting checkpoint inhibitor response in kidney cancer. <b>2017</b> , 18, 982-983	3
1177	Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. <b>2017</b> , 111, 176-181	37 <sup>o</sup>
1176	Tools to define the melanoma-associated immunopeptidome. <b>2017</b> , 152, 536-544	8
1175	The role of the tumour microenvironment in immunotherapy. <b>2017</b> , 24, T283-T295	43
1174	Integrative clinical genomics of metastatic cancer. <b>2017</b> , 548, 297-303	44 <sup>o</sup>
1173	Evasion of immunosurveillance by genomic alterations of PPAR $\alpha$ /RXR $\beta$ in bladder cancer. <b>2017</b> , 8, 103	66
1172	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. <b>2017</b> , 28, 2472-2480	35
1171	The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy. <b>2017</b> , 3, 643-658	8 <sup>o</sup>
1170	The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer. <b>2017</b> , 2, 99-103	10
1169	Recent developments in the treatment of metastatic colorectal cancer. <b>2017</b> , 9, 551-564	68
1168	Immuntherapien bei Gliomen. <b>2017</b> , 23, 831-837	
1167	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. <b>2017</b> , 29, 97-104	29
1166	The importance for immunoregulation for long-term cancer control. <b>2017</b> , 13, 1619-1632	8
1165	Identification of essential genes for cancer immunotherapy. <b>2017</b> , 548, 537-542	46 <sup>o</sup>
1164	Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. <b>2017</b> , 13, 1649-1663	6
1163	Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. <b>2017</b> , 47, 221-223	25
1162	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <b>2017</b> , 44, 2310-2325	34

1161	Genetic biomarker for cancer immunotherapy. <i>Science</i> , <b>2017</b> , 357, 358	33-3	5
1160	Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. <b>2017</b> , 28, 2539-2546		54
1159	Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. <b>2017</b> , 9, 533-550		56
1158	[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs]. <b>2017</b> , 104, 807-811		0
1157	PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. <b>2017</b> , 112, 200-215		122
1156	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <b>2017</b> , 19, 64		71
1155	Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. <b>2017</b> , 47, 103-109		26
1154	Immunogenetic Profiling for Gastric Cancers Identifies Sulfated Glycosaminoglycans as Major and Functional B Cell Antigens in Human Malignancies. <b>2017</b> , 20, 1073-1087		32
1153	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <b>2017</b> , 24, 235-251		293
1152	Immunotherapy for Uveal Melanoma. <b>2017</b> , 57, 29-39		9
1151	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <b>2017</b> , 18, 51		56
1150	Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy. <b>2017</b> , 77, 7083-7093		14
1149	Oncogenic RAS Signaling Promotes Tumor Immuno-resistance by Stabilizing PD-L1 mRNA. <b>2017</b> , 47, 1083-1099. e161		261
1148	Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. <b>2017</b> , 6, e161		38
1147	Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. <b>2017</b> , 8, 1954		174
1146	Targeting immune checkpoints in breast cancer: an update of early results. <b>2017</b> , 2, e000255		79
1145	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <b>2017</b> , 552, 116-120		290
1144	The Pancreatic Cancer Microenvironment. <b>2017</b> , 23, 321-325		85

1143	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <b>2017</b> , 171, 1284-1300.e21	215
1142	Personalised medicine for nonsmall cell lung cancer. <b>2017</b> , 26,	28
1141	Actionable gene-based classification toward precision medicine in gastric cancer. <b>2017</b> , 9, 93	41
1140	32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One. <b>2017</b> , 5,	17
1139	Personalized peptide vaccines for cancer therapy: current progress and state of the art. <b>2017</b> , 2, 371-381	6
1138	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <b>2017</b> , 8, 1324	314
1137	Cardiotoxicity of immune checkpoint inhibitors. <b>2017</b> , 2, e000247	126
1136	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. <b>2017</b> , 12, 2006-2013	6
1135	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <b>2017</b> , 551, 512-516	533
1134	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <b>2017</b> , 551, 517-520	336
1133	Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. <b>2017</b> , 92, 1564-1582	18
1132	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. <b>2017</b> , 16, 272-294	3
1131	First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. <b>2017</b> , 6, e1338235	35
1130	Genomics in upper tract urothelial carcinoma. <b>2017</b> , 27, 35-40	6
1129	Neue Entwicklungen in der systemischen Therapie des kleinzelligen Lungenkarzinoms. <b>2017</b> , 23, 355-359	
1128	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <b>2017</b> , 18, 1009-1021	492
1127	Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. <b>2017</b> , 3, e164	27
1126	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. <b>2017</b> , 6, 23-31	1

1125	An immunogenic personal neoantigen vaccine for patients with melanoma. <b>2017</b> , 547, 217-221	1375
1124	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <b>2017</b> , 547, 222-226	1153
1123	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. <b>2017</b> , 404, 62-69	83
1122	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. <b>2017</b> , 405, 29-37	51
1121	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. <b>2017</b> , 66, 13-33	34
1120	Biomarkers of response to PD-1/PD-L1 inhibition. <b>2017</b> , 116, 116-124	185
1119	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <b>2017</b> , 14, 655-668	498
1118	Personalisierte Medizin: Strukturen, Tumorboards, Visionen. <b>2017</b> , 32, 208-216	0
1117	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. <b>2017</b> , 36, 17-24	18
1116	Patient-Derived Xenograft Models of Human Cancer. <b>2017</b> ,	5
1115	Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer. <b>2017</b> , 17, 252	13
1114	Immunotherapy in head and neck cancer: aiming at EXTREME precision. <b>2017</b> , 15, 110	47
1113	Immunotherapy biomarkers 2016: overcoming the barriers. <b>2017</b> , 5, 29	17
1112	Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. <b>2017</b> , 5, 31	35
1111	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. <b>2017</b> , 5,	8
1110	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. <b>2017</b> , 5, 44	139
1109	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. <b>2017</b> , 36, 5-15	33
1108	A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. <b>2017</b> , 111, 1-5	43

1107	Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. <b>2017</b> , 23, 32-39	24
1106	Discovery of putative breast cancer antigens using an integrative platform of genomics-driven immunoproteomics. <b>2017</b> , 17, 1600318	5
1105	Relevance of DNA damage repair in the management of prostate cancer. <b>2017</b> , 41, 287-301	11
1104	A Richter transformation PD-1 block party. <b>2017</b> , 129, 3397-3398	
1103	Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. <b>2017</b> , 22, 3-11	29
1102	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. <b>2017</b> , 77, 839-850	145
1101	Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. <b>2017</b> , 599, 28-35	33
1100	Gene-expression profiling to predict responsiveness to immunotherapy. <b>2017</b> , 24, 134-140	55
1099	A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer. <b>2017</b> , 28, 298-304	20
1098	Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. <b>2017</b> , 17, 47-59	27
1097	Immune-Suppressing Cellular Elements of the Tumor Microenvironment. <b>2017</b> , 1, 241-255	18
1096	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. <b>2017</b> , 1, 223-240	16
1095	'Genotype/immunotype' correlations in resected NSCLC. <b>2017</b> , 28, 7-8	
1094	Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. <b>2017</b> , 12, 258-268	52
1093	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. <b>2017</b> , 38, 25-40	62
1092	Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. <b>2017</b> , 39, E34-E39	9
1091	Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies. <b>2017</b> , 151, 891-897	11
1090	Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. <b>2017</b> , 71, 169-176	13



1089	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <b>2017</b> , 28, 57-74	32
1088	The challenges of tumor genetic diversity. <b>2017</b> , 123, 917-927	41
1087	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. <b>2017</b> , 18, 132-140	15
1086	Breaking Down the Barriers to Precision Cancer Nanomedicine. <b>2017</b> , 35, 159-171	198
1085	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <b>2017</b> , 22, 81-88	95
1084	Massive parallel sequencing of solid tumours - challenges and opportunities for pathologists. <b>2017</b> , 70, 123-133	9
1083	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. <b>2017</b> , 67, 65-85	211
1082	Novel insights and therapeutic interventions for pediatric osteosarcoma. <b>2017</b> , 13, 357-368	130
1081	PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus. <b>2017</b> , 60, 16-23	35
1080	Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. <b>2017</b> , 28, 136-141	53
1079	The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma. <b>2017</b> , 176, 1354-1356	19
1078	Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. <b>2017</b> , 28, 83-89	63
1077	Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. <b>2017</b> , 28, 75-82	96
1076	Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. <b>2017</b> , 18, 220-233.e8	60
1075	Personalized cancer vaccines: Targeting the cancer mutanome. <b>2017</b> , 35, 1094-1100	39
1074	Immunotherapy Comes of Age in Lung Cancer. <b>2017</b> , 18, 13-22	49
1073	Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <b>2017</b> , 71, e26	1
1072	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. <b>2017</b> , 23, 370-378	101

1071	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. <b>2017</b> , 3, 244-255	141
1070	Inactivation of Capicua drives cancer metastasis. <b>2017</b> , 49, 87-96	92
1069	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. <b>2017</b> , 62, 397-405	31
1068	Next generation predictive biomarkers for immune checkpoint inhibition. <b>2017</b> , 36, 179-190	67
1067	CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. <b>2017</b> , 6, e1249558	52
1066	PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. <b>2017</b> , 77, 312-319	21
1065	The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. <b>2017</b> , 103, 27-37	89
1064	Chemical Carcinogenesis Models of Cancer: Back to the Future. <b>2017</b> , 1, 295-312	13
1063	Genomic Amplification of (PD-L1) in Small-Cell Lung Cancer. <b>2017</b> , 23, 1220-1226	74
1062	Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer. <b>2017</b> , 39, 247-253	69
1061	Biomarkers in Genitourinary Cancers: Blazing the Path Forward. <b>2017</b> , 71, 247-248	2
1060	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. <b>2017</b> , 23, 1820-1828	56
1059	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <b>2017</b> , 8, 2193	62
1058	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <b>2017</b> ,	6
1057	Informatics for cancer immunotherapy. <b>2017</b> , 28, xii56-xii73	11
1056	Traitement de première ligne et de maintenance dans les CBNPC avancés en l'absence d'addiction oncogénique. <b>2017</b> , 9, 234-247	
1055	Immunothérapie et cancer du poumon : où en sommes-nous ?. <b>2017</b> , 9, 315-324	0
1054	Immunotherapy in ovarian cancer. <b>2017</b> , 28, viii1-viii7	144

1053	Preclinical and clinical development of neoantigen vaccines. <b>2017</b> , 28, xii11-xii17	101
1052	High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. <b>2017</b> , 7, e612	99
1051	Biology and evolution of poorly differentiated neuroendocrine tumors. <b>2017</b> , 23, 1-10	109
1050	Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. <b>2017</b> , 64, 165-176	23
1049	Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. <b>2017</b> , 9, 769-779	9
1048	Regulation of CTL Infiltration Within the Tumor Microenvironment. <b>2017</b> , 1036, 33-49	18
1047	Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment. <b>2017</b> , 1036, 91-104	17
1046	COLUMNS. <b>2017</b> , 21, 27-33	
1045	Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where We're Headed. <b>2017</b> , 2, 79-86	1
1044	Checkpointinhibitoren beim nichtkleinzelligen Lungenkarzinom. <b>2017</b> , 23, 838-844	
1043	Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. <b>2017</b> , 17, 274-275	12
1042	Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma. <b>2017</b> , 23, 4619-4632	22
1041	Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. <b>2017</b> , 1,	0
1040	Whence High-Grade Serous Ovarian Cancer. <b>2017</b> , 37, 443-448	8
1039	Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. <b>2017</b> , 6, 29	8
1038	Systemic Therapy Options for Patients With Unresectable Melanoma. <b>2017</b> , 37, 661-672	5
1037	Integration of Genomics Into Treatment: Are We There Yet?. <b>2017</b> , 37, 569-574	1
1036	Erratum. <b>2017</b> , 92, 290-290	

1035	Cancer Immunotherapy in Older Patients. <b>2017</b> , 23, 219-222	4
1034	The future of immuno-oncology. <b>2017</b> ,	
1033	Immune Regulation in Breast Cancer Metastasis and Immunotherapy. <b>2017</b> ,	
1032	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. <b>2017</b> , 1, 1884-1890	19
1031	Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. <b>2017</b> , 28, xii3-xii10	24
1030	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <b>2017</b> , 11, 787	24
1029	New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. <b>2017</b> , 8, 67-78	20
1028	Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. <b>2017</b> , 10, 2097-2106	32
1027	Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. <b>2017</b> , 17, 378-391	50
1026	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <b>2017</b> , 8, 1-11	6
1025	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <b>2017</b> , 7, 1-11	29
1024	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <b>2017</b> , 8, 1597	145
1023	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <b>2017</b> , 7, 3585-3594	127
1022	Viroimmunotherapy of Thoracic Cancers. <b>2017</b> , 5,	4
1021	The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. <b>2017</b> , 9,	72
1020	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. <b>2017</b> , 9,	15
1019	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <b>2017</b> , 8, 267	47
1018	Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?. <b>2017</b> , 8, 830	35

1017	The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy. <b>2017, 8, 1113</b>	12
1016	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. <b>2017, 8, 1547</b>	80
1015	An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes. <b>2017, 8, 1566</b>	51
1014	Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. <b>2017, 8, 1679</b>	113
1013	Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients. <b>2017, 8, 1702</b>	29
1012	The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. <b>2017, 8, 1718</b>	23
1011	Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?. <b>2017, 8, 1848</b>	58
1010	Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. <b>2017, 8, 1897</b>	40
1009	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. <b>2017, 4, 4</b>	24
1008	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. <b>2017, 7, 67</b>	25
1007	The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform. <b>2017, 7, 190</b>	68
1006	Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. <b>2017, 7, 193</b>	203
1005	Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. <b>2017, 7, 253</b>	32
1004	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <b>2017, 2017, 3145742</b>	17
1003	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <b>2017, 2017, 4719194</b>	53
1002	Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. <b>2017, 2017, 5210459</b>	18
1001	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. <b>2017, 10, 2513-2526</b>	25
1000	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <b>2017, 9, 433-442</b>	13

999	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. <b>2017</b> , 8, 3251-3260	17
998	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <b>2017</b> , 10, 3697-3708	4
997	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. <b>2017</b> , 8, 48248-48252	65
996	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <b>2017</b> , 8, 93149-93155	45
995	A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. <b>2017</b> , 9, 2560-2571	16
994	Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells. <b>2017</b> , 12, e0183976	4
993	Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future. <b>2017</b> , 84, 130-141	7
992	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <b>2017</b> , 12, e0188174	65
991	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. <b>2017</b> , 14, e1002309	170
990	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. <b>2017</b> , 8, 1738	172
989	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. <b>2017</b> , 17, 618	25
988	The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. <b>2017</b> , 15, 133	117
987	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. <b>2017</b> , 10, 136	33
986	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. <b>2017</b> , 10, 146	57
985	The neoepitope landscape in pediatric cancers. <b>2017</b> , 9, 78	51
984	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. <b>2017</b> , 9, 89	23
983	Progressive hypoventilation due to mixed CD8 and CD4 lymphocytic polymyositis following tremelimumab - durvalumab treatment. <b>2017</b> , 5, 54	26
982	Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. <b>2017</b> , 5, 75	42

981	Biomarkers for immunotherapy in bladder cancer: a moving target. <b>2017</b> , 5, 94	100
980	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. <b>2017</b> , 5, 103	4
979	Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?. <b>2017</b> , 5, 84	4
978	Nivolumab Therapy for Synchronous -Positive Lung Cancer and Gastric Cancer. <b>2017</b> , 10, 361-367	3
977	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. <b>2017</b> , 12, 403-407	43 <sup>2</sup>
976	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <b>2017</b> , 8, 90532-90544	60
975	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, efficacy and Resistance. <b>2017</b> , 06,	
974	Checkpoint Inhibitors in Nonsmall Cell Lung Cancer. <b>2017</b> ,	
973	The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?. <b>2017</b> , 14, 341-347	3
972	Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer. <b>2017</b> , 9,	5
971	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <b>2017</b> , 1, 471-486	3
970	Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. <b>2017</b> , 8, 59268-59281	15
969	IFN- $\gamma$ -related mRNA profile predicts clinical response to PD-1 blockade. <b>2017</b> , 127, 2930-2940	1426
968	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <b>2017</b> , 1, 15-29	4
967	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. <b>2017</b> , 11, 1175-1182	10
966	PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. <b>2017</b> , 18,	46
965	Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. <b>2017</b> , 8, 332-344	17
964	Research progress in the treatment of small cell lung cancer. <b>2017</b> , 8, 29-38	11

963	Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer. <b>2017</b> , 8, 124-130	16
962	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <b>2017</b> , 8, 110693-110707	75
961	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <b>2017</b> , 8, 41641-41669	13
960	PD-1 inhibitors in endometrial cancer. <b>2017</b> , 8, 106169-106170	11
959	Is Circulating Tumor DNA (Ctdna) Use Ready For Prime Time? Applications and Challenges of Ctdna in the Era of Precision Oncology. <b>2017</b> , 06,	
958	Recent advances in the biology and therapy of medullary thyroid carcinoma. <b>2017</b> , 6, 2184	13
957	Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. <b>2017</b> , 37, 12-17	1
956	Precision Oncology: Who, How, What, When, and When Not?. <b>2017</b> , 37, 160-169	66
955	Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology. <b>2017</b> , 35, 929-933	37
954	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. <b>2017</b> , 35, 3823-3829	298
953	Hypermutation and microsatellite instability in gastrointestinal cancers. <b>2017</b> , 8, 112103-112115	46
952	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <b>2017</b> , 35, 3449-3457	223
951	Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. <b>2017</b> , 1,	14
950	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <b>2017</b> , 35, 2535-2541	244
949	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <b>2017</b> , 35, 3867-3876	263
948	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <b>2017</b> , 35, 2117-2124	415
947	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <b>2017</b> , 37, 548-560	16
946	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <b>2017</b> , 2017,	28



945	Circulating Tumor DNA in Non-Small-Cell Lung Cancer: A Primer for the Clinician.. <b>2017</b> , 1, 1-13	6
944	Novel Considerations in the Approach to Glioblastoma. <b>2017</b> , 13, 639-640	
943	Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of and. <b>2017</b> , 2017,	1
942	Biomarkers for Checkpoint Inhibition. <b>2017</b> , 37, 205-209	8
941	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. <b>2017</b> , 1,	10
940	Risk of cumulative toxicity after complete melanoma response with pembrolizumab. <b>2017</b> , 2017,	3
939	The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. <b>2017</b> , 8, 38850-38862	23
938	Liquid biopsies in lung cancer-time to implement research technologies in routine care?. <b>2017</b> , 5, 278	20
937	Checkpoint cluster: biomarkers of response. <b>2017</b> , 1, 501-508	
936	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <b>2017</b> , 8, 199-212	18
935	Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?. <b>2017</b> , 9, E519-E521	3
934	Tumor-associated macrophages-additional effectors at anti-PD-1/PD-L1 therapy?. <b>2017</b> , 9, 4197-4200	4
933	Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. <b>2017</b> , 9, 4162-4164	
932	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <b>2017</b> , 6, 373-386	32
931	Molecular diagnostics of lung cancer in the clinic. <b>2017</b> , 6, 560-569	34
930	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. <b>2017</b> , 6, S78-S83	5
929	Small-cell lung cancer in the era of immunotherapy. <b>2017</b> , 6, S67-S70	2
928	Molecular Tests for the Choice of Cancer Therapy. <b>2017</b> , 23, 4794-4806	6

927	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.. <b>2017</b> , 1, 1-15	31
926	Oncogenic pathways as the basis of primary immune ignorance. <b>2017</b> , 1, 421-428	
925	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. <b>2017</b> , 8, 3197-3205	29
924	Improving radiotherapy in cancer treatment: Promises and challenges. <b>2017</b> , 8, 62742-62758	103
923	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <b>2017</b> , 8, 77415-77423	55
922	STINGing the Tumor's immune evasion mechanism. <b>2018</b> , 7, e1083673	4
921	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. <b>2018</b> , 196, 62-70	3
920	JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. <b>2018</b> , 17, 732-739	14
919	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. <b>2018</b> , 6, 389-401	42
918	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <b>2018</b> , 14, 553-566	20
917	Nivolumab in the treatment of advanced renal cell carcinoma. <b>2018</b> , 14, 1679-1689	2
916	Immune Checkpoint Inhibition in Hodgkin Lymphoma. <b>2018</b> , 2, e20	8
915	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <b>2018</b> , 8, 730-749	235
914	Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. <b>2018</b> , 27, 935-943.e4	106
913	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <b>2018</b> , 118, 820-824	117
912	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <b>2018</b> , 7, 690-697	56
911	Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. <b>2018</b> , 1719, 209-221	34
910	CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. <b>2018</b> , 40, 1010428318760420	12

909	Immunotherapy for thoracic oncology gone viral. <b>2018</b> , 10, 383-390	1
908	Time is up for PD-L1 testing standardization in lung cancer. <b>2018</b> , 29, 791-792	2
907	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells. <b>2018</b> ,	8
906	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. <b>2018</b> , 11, 345-359	18
905	The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. <b>2018</b> , 67, 1011-1022	24
904	Targeting Neoantigens for Personalised Immunotherapy. <b>2018</b> , 32, 99-109	7
903	Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial. <b>2018</b> , 30, 201-203	5
902	Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?. <b>2018</b> , 131, 1-6	3
901	Implementation of "clinical sequencing" in cancer genome medicine in Japan. <b>2018</b> , 109, 507-512	23
900	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. <b>2018</b> , 198, 928-940	38
899	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <b>2018</b> , 12, 1179554918759079	4
898	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. <b>2018</b> , 19, 16	5
897	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. <b>2018</b> , 67, 805-814	27
896	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. <b>2018</b> , 17, 869-882	14
895	Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. <b>2018</b> , 68, 217-231	69
894	The possibility of cancer immune editing in gliomas. A critical review. <b>2018</b> , 7, e1445458	25
893	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. <b>2018</b> , 20, 1429-1438	114
892	Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. <b>2018</b> , 24, 2505-2516	25

891	Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. <b>2018</b> , 126, 342-352	81
890	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. <b>2018</b> , 20, 1101-1112	36
889	The dark side of tumor-associated endothelial cells. <b>2018</b> , 35, 35-47	50
888	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. <b>2018</b> , 65, 54-64	40
887	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. <b>2018</b> , 52, 189-197	71
886	Neutral Theory and the Somatic Evolution of Cancer. <b>2018</b> , 35, 1308-1315	11
885	Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. <b>2018</b> , 233, 6337-6343	65
884	Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report. <b>2018</b> , 13, 1217-1221	83
883	Recent advances in precision oncology research. <b>2018</b> , 2, 11	28
882	Organoids in cancer research. <b>2018</b> , 18, 407-418	611
881	Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. <b>2018</b> , 57, 1225-1231	42
880	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <b>2018</b> , 3, e000344	60
879	Immunotherapy for Glioblastoma: Playing Chess, Not Checkers. <b>2018</b> , 24, 4059-4061	10
878	Towards predictive biomarkers for immunotherapy response in breast cancer patients. <b>2018</b> , 7, BMT05	4
877	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. <b>2018</b> , 110, 1386-1392	78
876	IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer. <b>2018</b> , 6, 645-657	19
875	PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. <b>2018</b> , 124, 2498-2506	56
874	Pembrolizumab for primary malignant melanoma of the central nervous system. <b>2018</b> , 139, 225-227	2

873	PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. <b>2018</b> , 120, 108-112	117
872	DNA mismatch repair in cancer. <b>2018</b> , 189, 45-62	171
871	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <b>2018</b> , 378, 1976-1986	865
870	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <b>2018</b> , 378, 2093-2104	1704
869	Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. <b>2018</b> , 21, 694-699	5
868	The function and dysfunction of memory CD8 T cells in tumor immunity. <b>2018</b> , 283, 194-212	80
867	Implementing Keytruda/Pembrolizumab Testing in Clinical Practice. <b>2018</b> , 23, 647-649	3
866	Melanoma: What do all the mutations mean?. <b>2018</b> , 124, 3490-3499	62
865	Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. <b>2018</b> , 4, eaao1736	196
864	Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity. <b>2018</b> , 24, 3560-3571	45
863	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <b>2018</b> , 10, 1758835918762094	74
862	PD-L1 expression testing in non-small cell lung cancer. <b>2018</b> , 10, 1758835918763493	90
861	Radiotherapy and checkpoint inhibitors: a winning new combination?. <b>2018</b> , 10, 1758835918768240	58
860	Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?. <b>2018</b> , 20, 14	18
859	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. <b>2018</b> , 9, 1317	57
858	Regulatory T cells: a potential target in cancer immunotherapy. <b>2018</b> , 1417, 104-115	123
857	Comprehensive Characterization of Cancer Driver Genes and Mutations. <b>2018</b> , 173, 371-385.e18	854
856	Sending Cancer into the Fetal Position. <b>2018</b> , 22, 479-480	

855	Clinical and Pathological Characteristics of - and -Mutated Non-Small Cell Lung Carcinoma (NSCLC). <b>2018</b> , 24, 3087-3096	80
854	Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. <b>2018</b> , 124, 2169-2173	60
853	Präzisionsonkologie und molekulare Tumorboards [Konzepte, Chancen und Herausforderungen]. <b>2018</b> , 39, 124-132	
852	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. <b>2018</b> , 10, 1758835918763723	2
851	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <b>2018</b> , 33, 581-598	261
850	Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation. <b>2018</b> , 115, E4032-E4040	6
849	Personalized cancer vaccines: adjuvants are important, too. <b>2018</b> , 67, 1911-1918	28
848	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <b>2018</b> , 33, 843-852.e4	525
847	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <b>2018</b> , 11, 475-486	52
846	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <b>2018</b> , 10, 1758835918763744	17
845	Cancer immunotherapy-targeted glypican-3 or neoantigens. <b>2018</b> , 109, 531-541	33
844	Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. <b>2018</b> , 109, 542-549	31
843	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. <b>2018</b> , 105, 263-274	10
842	Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. <b>2018</b> , 4, 119-137	144
841	Trailblazing Precision Oncology for Rare Tumor Subtypes. <b>2018</b> , 23, 143-144	
840	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <b>2018</b> , 115, 2467-2472	82
839	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. <b>2018</b> , 19, 347-355	169
838	Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. <b>2018</b> , 13, 636-648	54

837	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. <b>2018</b> , 199, 1129-1142	28
836	Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. <b>2018</b> , 52, 259-268	9
835	Therapeutic cancer vaccines: From initial findings to prospects. <b>2018</b> , 196, 11-21	43
834	Tumor Mutational Burden Guides Therapy in a Treatment Refractory Mutant Uterine Carcinosarcoma. <b>2018</b> , 23, 518-523	30
833	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. <b>2018</b> , 126, 253-263	55
832	Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. <b>2018</b> , 64, 21-29	31
831	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. <b>2018</b> , 118, 57-61	31
830	[The biological rationale for immunotherapy in cancer]. <b>2018</b> , 35, 206-222	4
829	Immuno-oncology-101: overview of major concepts and translational perspectives. <b>2018</b> , 52, 1-11	30
828	A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. <b>2018</b> , 11, 311-329	119
827	Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. <b>2018</b> , 36, 103-108	15
826	TGFβ <sub>1</sub> attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <b>2018</b> , 554, 544-548	1697
825	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. <b>2018</b> , 215, 859-876	104
824	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <b>2018</b> , 13, 1-20	23
823	Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. <b>2018</b> , 29, i20-i27	54
822	Intermittent Exposure to Cigarette Smoke Increases Lung Tumors and the Severity of Emphysema More than Continuous Exposure. <b>2018</b> , 59, 179-188	11
821	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. <b>2018</b> , 7, 2	42
820	The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer. <b>2018</b> , 6, 358-369	31

819	T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. <b>2018</b> , 87, e12643	16
818	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <b>2018</b> , 10, 1758834017749748	128
817	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. <b>2018</b> , 7, e1435227	12
816	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. <b>2018</b> , 24, 2719-2731	37
815	Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. <b>2018</b> , 11, 237-248	10
814	Role of immune-checkpoint inhibitors in lung cancer. <b>2018</b> , 12, 1753465817750075	58
813	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. <b>2018</b> , 4, 101-109	22
812	Anti-PD1 in the wonder-gut-land. <b>2018</b> , 28, 263-264	16
811	TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic -Mutant Mouse Lung Cancer Models. <b>2018</b> , 6, 163-177	12
810	Biomarkers for assessing the effectiveness of immunotherapy in breast cancer. <b>2018</b> , 12, 97-100	1
809	Established, emerging and elusive molecular targets in the treatment of lung cancer. <b>2018</b> , 244, 565-577	11
808	Immune checkpoint inhibitors for metastatic bladder cancer. <b>2018</b> , 64, 11-20	57
807	Expansion of human $\Gamma$ cells for adoptive immunotherapy using a bisphosphonate prodrug. <b>2018</b> , 109, 587-599	22
806	Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. <b>2018</b> , 7, e1431084	20
805	Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. <b>2018</b> , 124, 2086-2103	94
804	Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. <b>2018</b> , 18, 297-305	17
803	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. <b>2018</b> , 29, 812-824	43
802	Translation in Immunology. <b>2018</b> , 1-11	



801	Cell-Based Therapies for Canine Cancer. <b>2018</b> , 252-267	
800	Somatic Mutations and Immunotherapy. <b>2018</b> , 24-36	1
799	Myeloid Leukemia Vaccines. <b>2018</b> , 54-71	
798	Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. <b>2018</b> , 7, 746-756	217
797	Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. <b>2018</b> , 29, 271-279	54
796	Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. <b>2018</b> , 29, 1030-1036	71
795	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <b>2018</b> , 19, 416-426	291
794	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. <b>2018</b> , 47, 142-157	16
793	Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. <b>2018</b> , 7, e1423173	13
792	Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. <b>2018</b> , 24, 1271-1276	24
791	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <b>2018</b> , 24, 47-53	170
790	PD-1/PD-L1 Axis in Lung Cancer. <b>2018</b> , 24, 15-19	39
789	PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. <b>2018</b> , 24, 41-46	65
788	The biology and management of non-small cell lung cancer. <b>2018</b> , 553, 446-454	1499
787	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. <b>2018</b> , 18, 267-276	11
786	Nivolumab for the treatment of urothelial cancers. <b>2018</b> , 18, 215-221	14
785	Prognosis of ovarian cancer is associated with effector memory CD8 T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. <b>2018</b> , 7, e1424672	45
784	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <b>2018</b> , 110, 787-790	82

783	Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond. <b>2018</b> , 24, 20-30	14
782	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <b>2018</b> , 24, 1326-1336	198
781	Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer. <b>2018</b> , 6, 276-287	46
780	Shared cancer neoantigens: Making private matters public. <b>2018</b> , 215, 5-7	27
779	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. <b>2018</b> , 19, 280-288.e4	38
778	Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation. <b>2018</b> , 20, 37-42	18
777	Proceedings of the National Cancer Institute Workshop on Charged Particle Radiobiology. <b>2018</b> , 100, 816-831	16
776	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <b>2018</b> , 23, 410-421	15
775	Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. <b>2018</b> , 13, 85-96	29
774	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. <b>2018</b> , 52, 125-134	33
773	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. <b>2018</b> , 231-246	
772	Peptide-Based Therapeutic Cancer Vaccines. <b>2018</b> , 249-261	2
771	Immune Checkpoint Inhibition in Lung Cancer. <b>2018</b> , 333-344	
770	BCG and Anti-PDL-1 Ab in Bladder Cancers. <b>2018</b> , 357-369	
769	PD-L1 and Other Immunological Diagnosis Tools. <b>2018</b> , 371-385	2
768	Synergy Between Radiotherapy and Immunotherapy. <b>2018</b> , 507-524	
767	Mutant Epitopes in Cancer. <b>2018</b> , 41-67	3
766	Immune Monitoring of Blood and Tumor Microenvironment. <b>2018</b> , 681-694	

765	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. <b>2018</b> , 7, e1395125	19
764	A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. <b>2017</b> , 7, e1371895	20
763	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Targeting the Right Antigens in the Right Patients. <b>2018</b> , 10,	5
762	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. <b>2018</b> , 52, 26-38	26
761	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. <b>2018</b> , 4, 210-216	277
760	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. <b>2018</b> , 52, 241-252	9
759	Whole-exome sequencing demonstrates recurrent somatic copy number alterations and sporadic mutations in specialized stromal tumors of the prostate. <b>2018</b> , 76, 9-16	3
758	Will liquid biopsies become our fluid transition to personalized immunotherapy?. <b>2018</b> , 29, 11-13	1
757	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <b>2018</b> , 10, 1758834017745012	73
756	Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. <b>2018</b> , 72, 1024-1032	21
755	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. <b>2018</b> , 137, 269-278	23
754	Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. <b>2018</b> , 23, 481-488	42
753	TIM-3 Regulates CD103 Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. <b>2018</b> , 33, 60-74.e6	141
752	Inhibitors of the PD-1 Pathway in Tumor Therapy. <b>2018</b> , 200, 375-383	82
751	Hitting the Target: How T Cells Detect and Eliminate Tumors. <b>2018</b> , 200, 392-399	37
750	Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. <b>2018</b> , 418, 1-9	39
749	Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. <b>2018</b> , 19, e349-e358	36
748	KEYNOTE-024: Unlocking a pathway to lung cancer cure?. <b>2018</b> , 155, 1777-1780	5

747	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. <b>2018</b> , 29, 301-310	56
746	Molecular Biomarkers in the Clinical Management of Prostate Cancer. <b>2018</b> , 8,	10
745	Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. <b>2018</b> , 200, 450-458	48
744	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. <b>2018</b> , 20, 966-974	18
743	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. <b>2018</b> , 116, 1-6	35
742	High response rate to PD-1 blockade in desmoplastic melanomas. <b>2018</b> , 553, 347-350	178
741	Precision oncology in the age of integrative genomics. <b>2018</b> , 36, 46-60	65
740	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. <b>2018</b> , 20, 472-483	31
739	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. <b>2018</b> , 33, 62-68	4
738	Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma. <b>2018</b> , 20, 184-194	27
737	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. <b>2018</b> , 110, 316-320	113
736	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , <b>2018</b> , 359, 801-806	33-3 562
735	High-Dimensional Profiling of Tumor-Specific Immune Responses: Asking T Cells about What They "See" in Cancer. <b>2018</b> , 6, 2-9	12
734	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. <b>2018</b> , 7, e1421891	40
733	Significance of Immune Checkpoints in Lung Cancer. <b>2018</b> , 59-77	
732	Immunotherapy for Other Malignancies. <b>2018</b> , 125-142	
731	A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. <b>2018</b> , 52, 158-165	4
730	Exosomes: Definition, Role in Tumor Development and Clinical Implications. <b>2018</b> , 11, 13-21	18

729	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <b>2018</b> , 33, 853-861.e4	471
728	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. <b>2018</b> , 18, 225	17
727	Population-level distribution and putative immunogenicity of cancer neoepitopes. <b>2018</b> , 18, 414	22
726	Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. <b>2018</b> , 17, 81	19
725	Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy. <b>2018</b> , 16, 81	14
724	Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. <b>2018</b> , 11, 46	40
723	The perfect personalized cancer therapy: cancer vaccines against neoantigens. <b>2018</b> , 37, 86	51
722	Image_1.jpg. <b>2020</b> ,	
721	Image_2.jpg. <b>2020</b> ,	
720	Image_3.tif. <b>2020</b> ,	
719	Image_4.jpg. <b>2020</b> ,	
718	Image_5.jpg. <b>2020</b> ,	
717	Table_1.DOCX. <b>2020</b> ,	
716	Table_2.DOCX. <b>2020</b> ,	
715	Table_3.DOCX. <b>2020</b> ,	
714	Table_4.DOCX. <b>2020</b> ,	
713	Table_5.DOCX. <b>2020</b> ,	
712	Table_6.DOCX. <b>2020</b> ,	

711	Table_1.XLSX. 2020,	
710	Data_Sheet_1.pdf. 2020,	
709	DataSheet_1.pdf. 2019,	
708	Data_Sheet_1.PDF. 2019,	
707	Data_Sheet_1.docx. 2018,	
706	Table_1.XLSX. 2019,	
705	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.. 2022,	0
704	Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.. 2022,	1
703	Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.. 2022, 2022, 8270305	1
702	Neoantigen Identification and Response to Adoptive Cell Transfer in anti PD-1 Naïve and Experienced Patients with Metastatic Melanoma.. 2022,	0
701	Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer.. 2022, 50, 3000605221093222	0
700	[Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer]. 2021, 24, 743-752	0
699	[Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].. 2022, 25, 46-53	
698	APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.. 2022, 12, 744-762	
697	Effect of mutations on tumor mutation burden and its potential prognostic significance for cutaneous melanoma.. 2022, 14, 849-862	
696	Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.. 2022, 10, 23247096221093886	1
695	Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.. 2022, 16, 11795549221092747	0
694	Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.. 2022, 183, 225-254	0

693	Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma. <b>2022</b> , 19, 7055-7075	1
692	Efficacy&nbsp;Comparison between Anti-PD-1 Antibody Monotherapy and Anti-PD-1 Plus Anti-CTLA-4 Combination Therapy as First-Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients.	
691	Development of a Novel Reference Material for Tumor Mutational Burden Measurement Based on CRISPR/Cas9 Technology.. <b>2022</b> , 12, 845636	
690	A Genomic Signature Reflecting Fibroblast Infiltration Into Gastric Cancer Is Associated With Prognosis and Treatment Outcomes of Immune Checkpoint Inhibitors.. <b>2022</b> , 10, 862294	
689	Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back.. <b>2022</b> , 13, 849515	1
688	RUNX1 as a novel molecular target for breast cancer. <b>2022</b> ,	0
687	Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.. <b>2022</b> , 42, 1-16	0
686	Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer.. <b>2022</b> , 9, 815290	0
685	Resistance Mechanisms to Anti-PD Cancer Immunotherapy.. <b>2022</b> , 40, 45-74	3
684	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies.. <b>2022</b> , 14,	
683	Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study. <b>2022</b> , 12, 679	1
682	MAPK signaling regulates the efficacy of chemoimmunotherapy.. <b>2022</b> , 9, 2054652	
681	Genetic and Clinical Characteristics of Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.. <b>2022</b> , 14,	0
680	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived eXplants.. <b>2022</b> ,	1
679	ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.. <b>2022</b> , 20, 170	1
678	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer.. <b>2022</b> , 9, 808378	0
677	Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.. <b>2022</b> , 9, 874213	0
676	Identification of TRP-Related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Lung Adenocarcinoma. <b>2022</b> , 9,	0

675	Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma.. <b>2022,</b>	0
674	Glutaminase inhibition impairs CD8 T'cell activation in STK11-/Lkb1-deficient lung cancer.. <b>2022,</b>	4
673	Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.. <b>2022,</b>	0
672	TIRSF: a web server for screening gene signatures to predict Tumor immunotherapy response.. <b>2022,</b>	0
671	Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies. <b>2022,</b> 2,	
670	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.. <b>2022,</b>	0
669	Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms.. <b>2022,</b> 1-11	1
668	Identification of neoantigens in esophageal adenocarcinoma.	
667	Focal Adhesion-Related Signatures Predict the Treatment Efficacy of Chemotherapy and Prognosis in Patients with Gastric Cancer. <b>2022,</b> 12,	1
666	Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.. <b>2022,</b> 23,	
665	Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.. <b>2022,</b> 22, 186	2
664	Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: a first-in-human clinical trial protocol.. <b>2022,</b>	0
663	Deciphering the tumor cell-infiltrating landscapes reveal microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.. <b>2022,</b>	0
662	Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors. <b>2022,</b> 21, 109-117	
661	Ultrasound-mediated immune regulation in tumor immunotherapy. <b>2022,</b> 14, 100248	0
660	Considerations for personalized neoantigen vaccination in Malignant glioma.. <b>2022,</b> 186, 114312	1
659	High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.. <b>2022,</b> 169, 64-73	2
658	Therapeutic bispecific antibodies against intracellular tumor antigens.. <b>2022,</b> 215699	2



657	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.. <b>2022</b> , 10,	2
656	OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.. <b>2022</b> , 108, 108813	1
655	Integrated Analysis Reveals Critical Ferroptosis Regulators and FTL Contribute to Cancer Progression in Hepatocellular Carcinoma. <b>2022</b> , 13,	0
654	Construction of an immune infiltration landscape based on immune-related genes in cervical cancer. <b>2022</b> , 105638	0
653	Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer. <b>2022</b> , 12,	
652	Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.. <b>2022</b> , 39, 92	
651	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer.. <b>2022</b> ,	5
650	The role of biomarkers in personalized immunotherapy.. <b>2022</b> , 10, 32	3
649	Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.. <b>2022</b> , 12, 1766-1783	
648	Pyroptosis impacts the prognosis and treatment response in gastric cancer via immune system modulation.. <b>2022</b> , 12, 1511-1534	
647	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. <b>2022</b> ,	3
646	DeepTMB: An uncertainty-aware deep calibration of tumor mutational burden with a synthetic tumor-only dataset.	
645	Comprehensive Analysis of the Butyrate-Metabolism-Related Gene Signature in Tumor Microenvironment-Infiltrating Immune Cells in Clear Cell Renal Cell Carcinoma. <b>2022</b> , 10,	0
644	Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes. <b>2022</b> , 13,	0
643	Prognostic and Immunological Role of PPP1R14A as a Pan-Cancer Analysis Candidate. <b>2022</b> , 13,	
642	Automated next-generation profiling of genomic alterations in human cancers. <b>2022</b> , 13,	1
641	High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma. <b>2022</b> , 13,	0
640	The role of neoantigens in tumor immunotherapy. <b>2022</b> , 151, 113118	2

- 639 HLA-I diversity and Tumor Mutational Burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. **2022**, 0
- 638 Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer. **13**,
- 637 Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM. **2022**, 2022, 1-14 0
- 636 neoMS: Attention-based Prediction of MHC-I Epitope Presentation.
- 635 Identification of lung cancer drivers by comparison of the observed and the expected numbers of missense and nonsense mutations in individual human genes. **2022**, 13, 756-767
- 634 Multi-Omics Analysis of MCM2 as a Promising Biomarker in Pan-Cancer. **2022**, 10, 1
- 633 Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced NonSmall Cell Lung Cancer. **2022**, 5, e2214046 0
- 632 A novel DNA damage and repair-related gene signature to improve predictive capacity of overall survival for patients with gliomas. 0
- 631 Combination of Stereotactic Ablative Radiotherapy With Anti-PD-1 in Oligoprogressive Non-Small-Cell Lung Cancer And Melanoma: Results of a Prospective Multicenter Observational Study. **2022**, 0
- 630 Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden. 0
- 629 Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. **2022**, 14, 2626 1
- 628 Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC). **2022**, 14, 2695
- 627 Programmed Death Ligand 1 (PD-L1) Expression and CD8+ Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy. **16**, Publish Ahead of Print,
- 626 Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy. **2022**, 2022, 1-15
- 625 Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-14 0
- 624 A local human V $\alpha$  T cell population is associated with survival in nonsmall-cell lung cancer. 1
- 623 Development and validation of a computed tomography-based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer. 0
- 622 Dysregulation and therapeutic targeting of RNA splicing in cancer. **2022**, 3, 536-546 3

621	Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors. <b>2022</b> , 10,	
620	Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. <b>2022</b> , 2022, 1-17	
619	Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma. 12,	0
618	Nanotechnology for Enhanced Cytoplasmic and Organelle Delivery of Bioactive Molecules to Immune Cells.	0
617	Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy. <b>2022</b> ,	
616	Profiling the Tumor-Infiltrating Lymphocytes in Gastric Cancer Reveals Its Implication in the Prognosis. <b>2022</b> , 13, 1017	0
615	Improving T-cell mediated immunogenic epitope identification via machine learning: the neoIM model.	
614	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. <b>2022</b> , 10, e004440	1
613	Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review). <b>2022</b> , 61,	1
612	Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample. <b>2022</b> , 13,	
611	Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. <b>2022</b> , 13,	0
610	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. <b>2022</b> , 11,	0
609	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. <b>2022</b> , 16, 117955492210998	2
608	Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope. <b>2022</b> , 393-411	
607	Immunotherapy in Melanoma and Merkel Cell Cancer. <b>2022</b> , 709-718	
606	Tumor Immune Microenvironment of Soft Tissue Sarcoma. <b>2022</b> , 639-647	
605	Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. <b>2022</b> , 1-15	0
604	Update on prognostic and predictive biomarkers of breast cancer. <b>2022</b> ,	0

603	Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. <b>2022</b> , 29, 4185-4198	3
602	Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. <b>2022</b> , 39, 110916	1
601	Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. <b>2022</b> , 10, e004582	1
600	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. <b>2022</b> , 13,	3
599	Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. <b>2022</b> , 23,	0
598	Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure As Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy. 2203309	11
597	Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. <b>2022</b> , 12,	0
596	The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis. 13,	2
595	Virus-Based Immuno-Oncology Models. <b>2022</b> , 10, 1441	0
594	Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations. <b>2022</b> , 6,	0
593	Dynamic changes of peripheral NK cells predict outcome in patients with PD-L1 positive Non-Small-Cell Lung Cancer undergoing immune checkpoint inhibitors as second-line therapy. 1-31	
592	Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. 13,	1
591	Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. <b>2022</b> , 14, 3123	0
590	A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity. 12,	0
589	Mitochondrial Homeostasis Related lncRNAs are Potential Biomarkers for Predicting Prognosis and Immune Response in Lung Adenocarcinoma. 13,	
588	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced NonSmall Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. <b>2022</b> , 5, e2215589	3
587	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.	9
586	Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition.	0

585	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <b>2022</b> , 13,	2
584	Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer. 28,	0
583	Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline &lt;i>&gt;BRCA1/2&lt;/i> Mutation.	
582	Big fish in small ponds: Narrow repertoires of stem-like tissue-resident T cells yield great power in anti-tumor immunity. <b>2022</b> , 55, 979-981	0
581	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <b>2022</b> , 132,	0
580	Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia. <b>2022</b> , 27, 659-671	0
579	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. <b>2022</b> , 14, 2816	0
578	Plac1 Remodels the Tumor Immune Evasion Microenvironment and Predicts Therapeutic Response in Head and Neck Squamous Cell Carcinoma. 12,	
577	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.	9
576	Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils. 13,	0
575	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.	15
574	Immune signature as a potential marker for predicting response to immunotherapy in obesity-associated colorectal cancer.	
573	ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion. 10,	
572	A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration. <b>2022</b> , 2022, 1-23	
571	Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. <b>2022</b> , 109, 102429	2
570	Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. <b>2022</b> , 172, 85-95	2
569	Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma. <b>2022</b> , 20, 3449-3460	
568	Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma. <b>2022</b> , 36, 514-532	2

- 567 Tumor-educated monocytes suppress T cells via adenosine and depletion of adenosine in the tumor microenvironment with adenosine deaminase enzyme promotes response to immunotherapy.
- 566 A review of concurrent chemo/radiation, immunotherapy, radiation planning, and biomarkers for locally advanced non-small cell lung cancer and their role in the development of ECOG-ACRIN EA5181. **2022**,
- 565 The status of tumor mutational burden and immunotherapy. **2022**, 3, 652-656 2
- 564 Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics.
- 563 Development and validation of a molecular tool to predict pathologic complete response in esophageal adenocarcinoma.
- 562 Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. **2022**, 10, 1539
- 561 Tumor Microenvironment Characterization in Breast Cancer and an Immune Cell Infiltration Score Development, Validation, and Application. 12,
- 560 Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
- 559 Therapeutic targeting of regulatory T cells in cancer. **2022**, 2
- 558 TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine. 0
- 557 HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer. **2022**, 14, 3495 0
- 556 mRNA vaccine development for cholangiocarcinoma: a precise pipeline. **2022**, 9, 0
- 555 Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development. **2022**, 2,
- 554 Immunotherapy approaches for malignant pleural mesothelioma. 1
- 553 Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer. **2022**, 14, 3294
- 552 Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in NonSmall Cell Lung Cancer. 13, 0
- 551 Recurrent somatic mutations as predictors of immunotherapy response. **2022**, 13, 0
- 550 Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. **2022**, 1

549	NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma. <b>2022,</b>	0
548	Ferroptosis-Related lncRNA Signature Correlates with the Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity of Esophageal Squamous Cell Carcinoma. <b>2022, 2022, 1-29</b>	0
547	PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.	
546	Differential Infiltration of Immune Cells Driven by Tumor Heterogeneity Reveals Two Immune Subtypes in Lung Adenocarcinoma. <b>13,</b>	
545	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab-Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <b>OF1-OF10</b>	5
544	DriverRWH: discovering cancer driver genes by random walk on a gene mutation hypergraph. <b>2022, 23,</b>	0
543	Mechanisms of resistance to immune checkpoint inhibitors.	0
542	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <b>2022, 23, 7839</b>	0
541	Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews. <b>13,</b>	0
540	DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. <b>Volume 15, 6127-6143</b>	
539	Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration.	
538	Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. <b>2022, 13,</b>	1
537	Targeting the CD47-SIRPβ Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. <b>2022, 14, 3366</b>	0
536	A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy. <b>13,</b>	0
535	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <b>2022, 54, 996-1012</b>	4
534	Molecular and Circulating Biomarkers in Patients with Glioblastoma. <b>2022, 23, 7474</b>	1
533	POLE/POLD1 mutation and tumor immunotherapy. <b>2022, 41,</b>	5
532	Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. <b>2022, 14, 3472</b>	1

- 531 The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
- 530 Improving the efficacy of immunotherapy in small cell lung cancer: Leveraging recent scientific discoveries and tumor-specific antigens. **2022**,
- 529 Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer. **2022**, 0
- 528 Delineating Molecular Subtypes through Gene Set Variation Analysis Confers Therapeutic and Prognostic Capability in Gastric Cancer. **2022**, 2022, 1-11
- 527 Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma. **2022**, 2022, 1-20 0
- 526 Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. **2022**, 15, 0
- 525 Mixed response to cancer immunotherapy is driven by intratumor heterogeneity and differential inter-lesion immune infiltration. 0
- 524 Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. **2022**, 12, 0
- 523 Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. **2022**, 0
- 522 Targeting DNA mismatch repair pathway by CRISPR nanosystem for boosting checkpoint blockade cancer immunotherapy. **2022**, 45, 101555
- 521 Applicability analysis of immunotherapy for lung cancer patients based on deep learning. **2022**, 205, 149-156
- 520 Colorectal cancer immunotherapy-Recent progress and future directions. **2022**, 545, 215816 1
- 519 Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy. **2022**, 10, e004831 0
- 518 Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles. 0
- 517 LncRNA profiles from Notch signaling: Implications for clinical management and tumor microenvironment of colorectal cancer. 13, 0
- 516 Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer. 9, 2
- 515 Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. 0
- 514 Advances in Cutaneous Squamous Cell Carcinoma Management. **2022**, 14, 3653 1



513	Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer. <b>2022</b> , 24, 101493	
512	Boosting anti-tumor immunity with an expanded neoepitope landscape.	
511	The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis. <b>2022</b> , 101, e29676	
510	Neoantigen-Specific T Cells in Adoptive Cell Therapy. <b>2022</b> , 28, 278-284	0
509	Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms. <b>2022</b> , 25, 40-61	
508	Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. <b>2022</b> , 8,	6
507	Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. <b>2022</b> , 13,	3
506	A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. <b>2022</b> , 20,	1
505	8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. 13,	
504	Clinical M2 Macrophage-Related Genes Can Serve as a Reliable Predictor of Lung Adenocarcinoma. 12,	0
503	Inhibition of stearyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating Eatenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. <b>2022</b> , 10, e004616	4
502	Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients. <b>2022</b> , 10,	0
501	Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. 13,	
500	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. 13,	
499	Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With NonSmall-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <b>2022</b> ,	0
498	Immunization Combined with Ferroptosis Related Genes to Construct a New Prognostic Model for Head and Neck Squamous Cell Carcinoma. <b>2022</b> , 14, 4099	
497	A pan-cancer analysis reveals the genetic alterations and immunotherapy of Piezo2 in human cancer. 13,	
496	Recent Advances and Challenges in Cancer Immunotherapy. <b>2022</b> , 14, 3972	3

495	Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. <b>2022</b> ,	1
494	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. 12,	2
493	Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients. <b>2022</b> ,	0
492	A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer. 13,	1
491	Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. <b>2022</b> , 28, 1619-1629	3
490	Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.	
489	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights.	0
488	PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis. 13,	1
487	Total mutational load and clinical features as predictors of the metastatic status in lung adenocarcinoma and squamous cell carcinoma patients. <b>2022</b> , 20,	
486	A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. <b>2022</b> , 14, 3862	0
485	The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.	0
484	Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. 12,	0
483	Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response. 9,	
482	Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer. 12,	
481	Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report. 12,	0
480	PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis. <b>2022</b> , 14, 3911	1
479	Pan-cancer integrative histology-genomic analysis via multimodal deep learning. <b>2022</b> , 40, 865-878.e6	3
478	Predictive value of focal adhesion-related genes for prognosis and response to immunotherapy in glioma patients.	

- 477 Successive relapses from donor and host cells in a patient with DEAD-box helicase 41 ( DDX41 )  
-associated myelodysplastic syndrome: The lessons to be learned.
- 476 Development and validation of a robust necroptosis related classifier for colon adenocarcinoma.  
13,
- 475 Tumor mutation burden-assisted risk stratification for papillary thyroid cancer. ○
- 474 Special issue "The advance of solid tumor research in China"FGFR4 alterations predict efficacy of  
immune checkpoint inhibitors in non-small cell lung cancer.
- 473 Next Steps for Immunotherapy in Glioblastoma. **2022**, 14, 4023 1
- 472 The cross-talk of cancer-associated fibroblasts assist in prognosis and immunotherapy in patients  
with breast carcinoma. ○
- 471 The pyroptosis-related gene signature predicts prognosis and reveals characterization of the tumor  
immune microenvironment in acute myeloid leukemia. 13, ○
- 470 A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden  
Threshold. 13, ○
- 469 Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker. ○
- 468 Immunotherapeutic targets in non-small cell lung cancer. 1
- 467 Solving the puzzle of what makes immunotherapies work. **2022**, ○
- 466 Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line  
treatment for non-squamous non-small cell lung cancer. **2022**, 2
- 465 Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1  
Immune Checkpoint Therapy. ○
- 464 Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in  
Nonsmall Cell Lung Cancer: A Multicentre Analysis. **2022**, 2022, 1-15
- 463 The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant  
Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. **2022**, 2022, 1-11
- 462 A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint  
blockade therapy of low-grade glioma. 9, ○
- 461 Single-cell analysis reveals clonally expanded tumor-associated CD57+ CD8 T cells are enriched in  
the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade. **2022**, 10, e004759 ○
- 460 Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and  
Immunotherapy. **2022**, 2022, 1-42 1

- 459 Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis. **2022**, 22,
- 458 Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. 12,
- 457 Immune cellular components and signaling pathways in the tumor microenvironment. **2022**, 1
- 456 Deep learning reveals cuproptosis features assist in predict prognosis and guide immunotherapy in lung adenocarcinoma. 13, 0
- 455 Development and validation of a novel fibroblast scoring model for lung adenocarcinoma. 12, 0
- 454 Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis. **2022**, 12, e058692 0
- 453 Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. **2022**, 0
- 452 High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade. **2022**, 23, 9124 0
- 451 X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer. 13,
- 450 Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land. **2022**, 153, 113464 0
- 449 Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers. **2022**, 546, 215853 0
- 448 The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA. **2022**, 65, 116-123 0
- 447 Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. **2022**, 10, e005328 0
- 446 The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis. **2022**, 2022, 1-7 0
- 445 Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. 11, 0
- 444 A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy. **2022**, 350, 734-747 1
- 443 Post-transcriptional gene regulation in solid tumors. **2022**, 119-148 0
- 442 Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study. **2022**, 14, 175883592211227 0

- 441 Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. **2022**, 0
- 440 Cancer prognosis and immune system. **2022**, 75-144 0
- 439 Anti-neoplastic Immunomodulatory Treatments and the Pituitary. **2022**, 309-320 0
- 438 Research Progress of Tumor Mutational Burden in Predicting Prognosis of Patients with Malignant Tumors. **2022**, 12, 7000-7004 0
- 437 Development of a prognostic signature for esophageal cancer based on a novel 7-DNA damage repair genes signature. **2022**, 46, 2601-2613 0
- 436 New opportunities for immunomodulation of the tumour microenvironment using chemical tools. **2022**, 51, 7944-7970 2
- 435 High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. 0
- 434 Cuproptosis scoring model predicts overall survival and assists in immunotherapeutic decision making in pancreatic carcinoma. 13, 0
- 433 Neoantigen vaccine and neoantigen-specific cell adoptive transfer therapy in solid tumors: Challenges and future directions. **2022**, 1, 168-182 0
- 432 Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma. **2022**, 0
- 431 High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. **2022**, 10, 2109 0
- 430 New Biomarkers and Immunotherapy Decision. **2022**, 1-15 0
- 429 Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. **2022**, 29, 6260-6276 0
- 428 Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. **2022**, 8, e10450 0
- 427 Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report. **2022**, 29, 6203-6210 0
- 426 Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. 2
- 425 Pyroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Non-Small-Cell Lung Cancer. **2022**, 2022, 1-27 0
- 424 The contribution of skeletal muscle to cancer immunotherapy: a focus on muscle function, inflammation and microbiota. **2022**, 111829 0

423	̄ cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1. <b>2022</b> ,	0
422	Recent Advances in DNA Vaccines against Lung Cancer: A Mini Review. <b>2022</b> , 10, 1586	0
421	Comprehensive analysis of the prognostic implications and functional exploration of PAK gene family in human cancer. <b>2022</b> , 22,	1
420	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <b>2022</b> , 7,	5
419	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma.	0
418	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. 13,	0
417	Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development. 12,	1
416	Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltration.	0
415	Identification of neoantigens in esophageal adenocarcinoma.	0
414	m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent. 13,	0
413	Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee. <b>2022</b> ,	1
412	Clinical predictive value of naïve and memory T cells in advanced NSCLC. 13,	0
411	Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunity.	0
410	Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients. 12,	2
409	Development and verification of an immune-related gene prognostic index for gastric cancer. <b>2022</b> , 12,	1
408	Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA. 13,	0
407	Thyroid-related adverse events induced by immune checkpoint inhibitors. 13,	0
406	Long-term benefit of immunotherapy in a patient with mismatch repair deficient/microsatellite instability-high/high tumor mutational burden lung cancer: case report and literature review.	0

405	Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade. <b>2022</b> , 2022, 1-9	0
404	Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia. 13,	1
403	Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. <b>2022</b> , 8,	0
402	Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.	0
401	Polycomb Directed Cell Fate Decisions in Development and Cancer. <b>2022</b> , 6, 28	2
400	Beyond PD-L1 : Assessment of LAG -3 and other predictive biomarkers in non-small cell lung carcinoma.	0
399	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. <b>2022</b> , 2022, 1-12	0
398	Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer. 12,	0
397	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. 13,	5
396	Neoadjuvant radiation therapy and surgery improves metastasis-free survival over surgery alone in a primary mouse model of soft-tissue sarcoma.	1
395	Big data in basic and translational cancer research.	3
394	Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.	0
393	Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study. 13,	0
392	Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.	8
391	Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas. <b>2022</b> , 12,	0
390	An Integrative Multi-Omics Analysis Based on Nomogram for Predicting Prostate Cancer Bone Metastasis Incidence. <b>2022</b> , 2022, 1-17	0
389	Recent advances in bacterial therapeutics based on sense and response. <b>2022</b> ,	1
388	A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy. <b>2022</b> , 23,	0

387	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. 13,	1
386	Molecular Biomarkers of Response to Cancer Immunotherapy. <b>2022</b> , 42, 469-484	0
385	Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy. 13,	0
384	Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy. <b>2022</b> , 11, 2802	0
383	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
382	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. <b>2022</b> , 14, 4616	0
381	Development and validation of a combined glycolysis and immune prognostic signature for lung squamous cell carcinoma. 13,	0
380	Construction and validation of a bladder cancer risk model based on autophagy related genes.	0
379	Tumor mutational burden by whole-genome sequencing in resected NSCLC of never smokers.	0
378	Extracellular vesicle-based checkpoint regulation and immune state in cancer. <b>2022</b> , 39,	0
377	Linc00996 is a favorable prognostic factor in LUAD: Results from bioinformatics analysis and experimental validation. 13,	0
376	Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. <b>2022</b> , e10932	1
375	Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.	1
374	DNA methylation regulator-mediated modification pattern defines tumor microenvironment immune infiltration landscape in colon cancer. 13,	0
373	Clinical neutrophil-associated genes as reliable predictors of hepatocellular carcinoma. 13,	0
372	Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing.	1
371	Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing.	0
370	Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective. <b>2022</b> , 215945	0



- 369 Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). 3
- 368 THE DNA DAMAGE INDUCED IMMUNE RESPONSE: IMPLICATIONS FOR CANCER THERAPY. **2022**, 103409 ○
- 367 Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study. 13, ○
- 366 Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer. Publish Ahead of Print, ○
- 365 Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients. **2022**, 176, 78-87 ○
- 364 Machine learning-based exceptional response prediction of nivolumab monotherapy with circulating microRNAs in non-small cell lung cancer. **2022**, 173, 107-115 ○
- 363 RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges. **2022**, 1877, 1888-10 ○
- 362 PTEN in Immunity. **2022**, 95-115 ○
- 361 Designer Microbes: Oncotherapy Approach. **2022**, 231-247 ○
- 360 Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer. **2022**, ○
- 359 Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. **2022**, 13, ○
- 358 Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma. **2022**, 29, 7718-7731 ○
- 357 An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer. ○
- 356 A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. 12, ○
- 355 Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. **2022**, ○
- 354 ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution. **2022**, ○
- 353 Identification of a novel pyroptosis related long noncoding RNA subtypes, development of a prognostic model and characteristics of the tumor microenvironment in gastric cancer. ○
- 352 Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer. **2022**, 12, 1459 1

351	Translational Research in Cancer Immunotherapies. <b>2022</b> , 62, 363-370	0
350	MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer. <b>2022</b> , 27,	0
349	Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé?. <b>2022</b> , 14, 2S225-2S232	0
348	Cancer Genomics and Evolution. 1-30	0
347	Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. 13,	0
346	Subcellular location of source proteins improves prediction of neoantigens for immunotherapy.	0
345	The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers. <b>2022</b> , 10,	0
344	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <b>2022</b> , 14, 4985	2
343	Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma. 13,	1
342	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. <b>2022</b> , 23, 13241	0
341	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. 13,	0
340	Precision Medicine in Oncology Drug Development. 1-15	0
339	Identification of novel a chromatin regulator signature predicting overall survival for breast cancer.	0
338	Clinical cancer immunotherapy: Current progress and prospects. 13,	2
337	Anticancer potentiating effect and downregulation of PD-L1 expression: Study on the 2-[(p-fluorophenyl)amino]-6-substituted-9 H -purine analogues as novel CHK1 inhibitors.	0
336	Genomic instability, origin and evolution of cancer, and personalized immunotherapy. <b>2022</b> ,	0
335	Clinical and Translational Advances in Glioma Immunotherapy.	1
334	Current Status of Immune Checkpoint Inhibitors. <b>2022</b> , 73, 303-307	0

333	CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer. <b>2022</b> , 14, 4866	1
332	Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma. <b>2022</b> , 23, 12991	0
331	Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.	0
330	Integrative Genomic Tests in Clinical Oncology. <b>2022</b> , 23, 13129	0
329	A novel oxidative stress- and ferroptosis-related gene prognostic signature for distinguishing cold and hot tumors in colorectal cancer. 13,	0
328	SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers. 13,	0
327	Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma. 12,	0
326	Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. <b>2022</b> , 25, 105382	0
325	Development and validation of blood tumor mutational burden reference standards.	0
324	Chemokine Physiology in Cancer.	0
323	Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. <b>2022</b> , 13,	1
322	Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. <b>2022</b> , 156, 113906	0
321	Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells. <b>2023</b> , 27, 101559	0
320	Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. <b>2022</b> , 8, 27	0
319	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. <b>2022</b> , 35, 803-813	2
318	Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. <b>2022</b> , 14, 5473	0
317	Identification of ceRNA-based H19/SIX4 regulatory axis as a prognostic biomarker for colorectal cancer via high throughput transcriptomic data.	0
316	Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. 13,	0

- 315 Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. 13, ○
- 314 Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. 13, ○
- 313 Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. **2022**, 100431 ○
- 312 Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. **2022**, 10, e005401 ○
- 311 Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction. 12, ○
- 310 Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. **2022**, 2022, 1-15 ○
- 309 A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer. **2022**, 15, 1401 ○
- 308 A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. **2022**, 22, ○
- 307 Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy. 10, ○
- 306 Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction. ○
- 305 Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. 13, ○
- 304 Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. **2022**, 14, ○
- 303 Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. 12, ○
- 302 External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme. ○
- 301 Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma. ○
- 300 CAR T-cells for colorectal cancer immunotherapy: Ready to go?. 13, ○
- 299 Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. **2022**, ○
- 298 Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development. 10, ○

- 297 Global research trends on immunotherapy in cancer: a visualization analysis. ○
- 296 DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. **2022**, 13, ○
- 295 Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. **2022**, ○
- 294 Challenges in neoantigen-directed therapeutics. **2022**, 1
- 293 Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. 12, 1
- 292 The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. **2022**, 174, 125-132 ○
- 291 Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. **2022**, ○
- 290 Potential impact of WTAP and YTHDF2 on tumor immunity in lung adenocarcinoma. **2022**, 101, e31195 ○
- 289 Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene sets. ○
- 288 Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients. **2022**, 14, 5638 1
- 287 Identification of PRIM2 as a new prognostic and immune-related marker in cancer based on a comprehensive pan-cancer analysis. ○
- 286 Identification of a novel oxidative stress-related prognostic model in lung adenocarcinoma. 13, 1
- 285 Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. **2022**, 14, 175883592211417 ○
- 284 Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review. **2023**, 4, 100146 ○
- 283 Recent progress in cancer immunotherapy: Overview of current status and challenges. **2023**, 241, 154241 ○
- 282 Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. **2023**, 36, 100864 ○
- 281 Pharmacogenomics and Cancer Treatment. **2022**, 1-16 ○
- 280 A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. **2022**, 21, 117693512211360 ○

- 279 Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. 100-107 ○
- 278 The Right Therapy Starts with the Right Test: Novel Therapeutic Approaches in Oncology Foster the Need for an Appropriate Molecular Profiling Strategy. 42-48 ○
- 277 Immunological role and prognostic value of SPARCL1 in pan-cancer analysis. 28, ○
- 276 Immune landscape and immunotherapy for penile cancer. 13, ○
- 275 Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer. **2022**, 14, ○
- 274 Single-cell analysis in lung adenocarcinoma implicates RNA editing in cancer innate immunity and patient prognosis. ○
- 273 Advances in the Lung Cancer Immunotherapy Approaches. **2022**, 10, 1963 ○
- 272 Treating Biliary Tract Cancers: New Targets and Therapies. **2022**, 82, 1629-1647 ○
- 271 Development of therapeutic antibodies for the treatment of diseases. **2022**, 3, 1
- 270 Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. **2022**, 13, ○
- 269 Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment. **2022**, 11, 3672 ○
- 268 Integrated modeling to implicate evolving neoantigen-T cell interplays and immunotherapy efficacy in tumors. ○
- 267 Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer. **2022**, 11, 3841 ○
- 266 Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations. ○
- 265 A pan-cancer analysis of the FAT1 in human tumors. **2022**, 12, ○
- 264 Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. **2022**, 6, ○
- 263 Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. ○
- 262 Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling. 12, ○

261	Prognostic value of TMEM59L and its genomic and immunological characteristics in cancer. 13,	○
260	Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene. 1-94	○
259	A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.	○
258	Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. 13,	○
257	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <b>2023</b> , 24, 41	1
256	Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma. <b>2022</b> , 12,	○
255	Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. 13,	1
254	Cancer Immunotherapy Beyond Checkpoint Blockade. <b>2022</b> , 4, 563-578	○
253	New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.	1
252	Fecal Microbiota Transplant in Immunotherapy-Resistant Melanoma: What Can We Expect in the Near Future?. <b>2022</b> ,	○
251	SP140 inhibits STAT1 signaling, induces IFN- $\gamma$ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response. <b>2022</b> , 10, e005088	○
250	Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. <b>2023</b> , 15, 104	○
249	Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.	○
248	The Emerging Role of NK Cells in Immune Checkpoint Blockade. <b>2022</b> , 14, 6005	○
247	Introduction on Personalized Immune-Oncology. <b>2023</b> , 1-25	○
246	Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. 13,	○
245	A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. <b>2022</b> , 2022, 1-19	○
244	Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. <b>2022</b> , 14,	○

243	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous NonSmall Cell Lung Cancer With High Tumor Mutation Burden.	0
242	Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer.	0
241	Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. 1-14	0
240	Somatic A-to-I RNA-edited RHOA isoform 2 specific-R176G mutation promotes tumor progression in lung adenocarcinoma.	0
239	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. 9,	0
238	Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia. 9,	0
237	The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer.	1
236	Resistance to immune checkpoint inhibitors and the tumor microenvironment.	0
235	Propagated circulating tumor cells uncovers the role of NF $\kappa$ B and COP1 in metastasis.	0
234	Current status and challenges of immunotherapy in ALK rearranged NSCLC. 12,	0
233	Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.. 2022,	0
232	Incorporating RNA-based risk scores for genomic instability to predict breast cancer recurrence and immunogenicity in a diverse population.	0
231	Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer. 2022, 2022, 1-50	2
230	Development of <sup>89</sup> Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration. 2022, 10, e004877	0
229	HLApollo: A superior transformer model for pan-allelic peptide-MHC-I presentation prediction, with diverse negative coverage, deconvolution and protein language features.	0
228	Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.	0
227	Immunotherapies targeting neoantigens are effective in PD -1 blockade-resistant tumors.	0
226	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. 13,	2



- 225 Immune related biomarkers for cancer metastasis to the brain. **2022**, 11, ○
- 224 CLINICAL AND TECHNICAL INSIGHTS OF TUMOUR MUTATIONAL BURDEN IN NON-SMALL CELL LUNG CANCER.. **2022**, 103891 ○
- 223 Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. **2022**, 7, 100641 ○
- 222 ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. **2022**, 22, ○
- 221 Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer. **2022**, 14, 1
- 220 IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma. 13, 1
- 219 Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy. **2022**, 20, ○
- 218 Non-small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB. **2022**, 12, ○
- 217 Novel immune-related prognostic model and nomogram for breast cancer based on ssGSEA. 13, ○
- 216 Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. ○
- 215 Progress and prospects for use of cellular immunotherapy in pancreatic cancer. **2022**, 18, 1867 ○
- 214 Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model. 13, ○
- 213 Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker. 13, ○
- 212 PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. **2023**, 42, ○
- 211 Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. **2023**, 1
- 210 Mechanisms of Resistance to Immunotherapies in Cancer. **2023**, 1-30 ○
- 209 Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. **2023**, 4, 100900 ○
- 208 Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. 13, ○

207	Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer. 13,	0
206	Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patients with Locally Advanced NonSmall Cell Lung Cancer Treated With Chemoradiation and Durvalumab. <b>2023</b> , 6, e2249591	0
205	The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer. <b>2023</b> , 24, 1506	0
204	Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. <b>2023</b> , 11, e005801	0
203	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. 13,	0
202	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.	1
201	Comprehensive analysis of immune-related lncRNAs and their clinical relevance in gastric adenocarcinoma. <b>2023</b> , 23,	0
200	Advances in artificial intelligence to predict cancer immunotherapy efficacy. 13,	0
199	Somatic mutation but not aneuploidy differentiates lung cancer in never-smokers and smokers.	0
198	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. 12,	0
197	The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer. 10,	0
196	Immune signatures in cutaneous melanoma correlate with survival independently of immunotherapy treatment.	1
195	Upregulation of complement proteins in lung cancer cells mediates tumor progression. 12,	0
194	Characterization of Pancreatic Cancer with Ultra-low Tumor Mutational Burden.	0
193	Standardized pathology screening of mature Tertiary Lymphoid Structures in cancers. <b>2023</b> , 100063	0
192	InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides. <b>2023</b> , 10,	0
191	PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. 13,	0
190	Recent advances in small cell lung cancer: the future is now?. <b>2023</b> , 47,	0

- 189 MHC II immunogenicity shapes the neoepitope landscape in human tumors. ○
- 188 An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma. **2023**, 14, 124 ○
- 187 Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies. **2023**, 158, 114150 ○
- 186 Programmed death ligand-1 expression and its association with the degree of differentiation and the presence of necrosis in non-small cell lung carcinoma. **2023**, 242, 154296 1
- 185 Second near-infrared nanomaterials for cancer photothermal immunotherapy. **2023**, 17, 100339 ○
- 184 Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients. ○
- 183 Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. ○
- 182 Advancements in Cancer Immunotherapies. **2023**, 11, 59 ○
- 181 5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma. **2023**, 30, 559-574 ○
- 180 Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers. **2022**, ○
- 179 The Role of Immune Checkpoint Inhibitors in Cancer Therapy. **2023**, 13, 22-40 2
- 178 Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. **2023**, 15, 246 ○
- 177 SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma. **2022**, 20, ○
- 176 Pretraining Transformers for TCR-pMHC Binding Prediction. **2022**, ○
- 175 Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. ○
- 174 Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. **2023**, 24, 2505 ○
- 173 Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. **2023**, 22, 153303382211505 ○
- 172 What is precision medicine in oncology?. **2023**, 1-30 ○

- 171 Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. **2023**, 11, e005924 ○
- 170 Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME). **2023**, ○
- 169 Clinical Plasma Cells-related Genes to Aid Therapy in Colon Cancer. ○
- 168 Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines. **2023**, 14, 3-11 ○
- 167 Role and modality of combining radiotherapy with immunotherapy in Stage III-IV Unresectable Small Cell Lung Cancer. ○
- 166 Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. 14, ○
- 165 Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification. ○
- 164 Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. Publish Ahead of Print, ○
- 163 Base editing screens map mutations affecting interferon- $\beta$  signaling in cancer. **2023**, ○
- 162 Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis. **2023**, 15, 175883592211489 ○
- 161 Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis. 12, ○
- 160 Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy. **2023**, 11, e005902 ○
- 159 Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. **2023**, 11, e005809 ○
- 158 Construction and validation of a bladder cancer risk model based on autophagy-related genes. **2023**, 23, ○
- 157 Persistent mutation burden drives sustained anti-tumor immune responses. 1
- 156 Research Status and Progress of PD-1/PD-L1 Inhibitors in the Treatment of Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer. **2023**, 13, 978-985 ○
- 155 The application of RNA sequencing in precision cancer medicine. **2023**, ○
- 154 Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC. **2023**, ○

- 153 Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. ○
- 152 Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma. **2023**, 154, 106602 ○
- 151 Immunotherapy: Targeting Cancer Cells. **2023**, 179-217 ○
- 150 A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. **2023**, 21, 2536-2546 ○
- 149 Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma. **2023**, 18, ○
- 148 Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shed. ○
- 147 Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known. **2023**, 7, e0063-e0063 ○
- 146 Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors. 14, ○
- 145 A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers. **2023**, 116, 109821 ○
- 144 Generation of peptides using phage display technology for cancer diagnosis and molecular imaging. ○
- 143 Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer. ○
- 142 Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer. **2023**, ○
- 141 Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. **2023**, 117, 109881 ○
- 140 Combination toripalimab and bevacizumab for an elderly urothelial carcinoma patient with brain metastasis who failed rapidly after radiotherapy: a case report and literature review. **2023**, 34, 317-324 ○
- 139 Targeting polymerase  $\beta$  impairs tumorigenesis and enhances radiosensitivity in lung adenocarcinoma. 1 ○
- 138 Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. **2022**, 14, 1427-1448 ○
- 137 Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity. **2023**, 9, e13201 ○
- 136 An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. **2023**, 88, 104452 ○

- 135 Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India. ○
- 134 Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer. **2023**, 15, 127-133 ○
- 133 Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Volume 14, 11-25 ○
- 132 Modulation of oxidative phosphorylation and mitochondrial biogenesis by cigarette smoke influence the response to immune therapy in NSCLC patients. **2023**, 178, 37-46 ○
- 131 Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. **2023**, 18, e0281459 ○
- 130 Construction of a cuproptosis-associated long non-coding RNA risk prediction model for pancreatic adenocarcinoma based on the TCGA database. **2023**, 102, e32808 ○
- 129 Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. **2023**, 3, ○
- 128 Genomic features and its potential implication in bone oligometastatic NSCLC. **2023**, 23, ○
- 127 Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. **2023**, 15, 1093 ○
- 126 Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer. 12, ○
- 125 Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. **2023**, 15, 1076 ○
- 124 Construction of a pyroptosis-related lncRNAs signature for predicting prognosis and immunotherapy response in glioma. **2023**, 102, e32793 ○
- 123 The Prognostic Value and the Oncogenic and Immunological Roles of Vacuolar Protein Sorting Associated Protein 26 A in Pancreatic Adenocarcinoma. **2023**, 24, 3486 ○
- 122 Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. **2023**, 11, 508 ○
- 121 Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. **2023**, 4, 100474 ○
- 120 The impact of impaired tissue fixation in resected non-small-cell lung cancer on protein deterioration and DNA degradation. **2023**, 178, 108-115 ○
- 119 Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report. 11, 1165-1174 ○
- 118 Association between Tumor Mutational Burden, Stromal CD8+ Tumor-Infiltrating Lymphocytes, and Clinical Factors in Cervical Cancers Treated with Radiotherapy. **2023**, 15, 1210 ○

117	Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives. <b>2023</b> , 1-36	1
116	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. <b>2023</b> , 30, 2366-2387	0
115	Bronchial artery chemoembolization with drug-eluting beads versus bronchial artery infusion followed by polyvinyl alcohol particles embolization for advanced squamous cell lung cancer: A retrospective study. <b>2023</b> , 161, 110747	0
114	Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. <b>2023</b> , 15, 547	0
113	Targeting the recurrent Rac1P29S neopeptide in melanoma with heterologous high-affinity T cell receptors. 14,	0
112	USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. <b>2023</b> , 24, 143-156	0
111	Risk score = LncRNAs associated with doxorubicin metabolism can be used as molecular markers for immune microenvironment and immunotherapy in non-small cell lung cancer. <b>2023</b> , 9, e13811	0
110	The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. <b>2023</b> , 28,	0
109	MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. <b>2023</b> , 9,	0
108	Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. 14,	0
107	Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. <b>2023</b> , 22,	0
106	Lung cancer immunotherapy: progress, pitfalls, and promises. <b>2023</b> , 22,	0
105	Immunotherapy in malignant peritoneal mesothelioma (Review). <b>2023</b> , 18,	0
104	RNA m6A methylation regulator-mediated modification patterns and tumor microenvironment characterization in hepatocellular carcinoma.	0
103	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. <b>2023</b> , 11, e006464	0
102	LINC01798/miR-17-5p axis regulates ITGA8 and causes changes in tumor microenvironment and stemness in lung adenocarcinoma. 14,	0
101	Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. <b>2023</b> , 20, 318-340	0
100	Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data. 14,	0

- 99 Deep learning in digital pathology for personalized treatment plans of cancer patients. **2023**, 40, 109-119 ○
- 98 Immunotherapy of Osteosarcoma. **2023**, 1-39 ○
- 97 Biomarkers for Monitoring the Immunotherapy Response to Cancer. **2023**, 1-37 ○
- 96 Impact of Tobacco, Marijuana, and Alcohol use on Overall Survival in Recurrent Metastatic head and neck Cancer Patients Treated with Immune Checkpoint Inhibitors. ○
- 95 Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer. **2023**, ○
- 94 Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes. **2023**, 30, 478-488 ○
- 93 CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. **2023**, 13, 465 ○
- 92 Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the NSCLC of GI Oncology?. **2023**, 15, 1578 ○
- 91 ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. **2023**, 5, ○
- 90 Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. ○
- 89 T cell effects and mechanisms in immunotherapy of head and neck tumors. **2023**, 21, ○
- 88 Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma. **2023**, 13, ○
- 87 LINC00261 expression reduces mutation accumulation while conferring resistance to cisplatin and altering the tumor-immune microenvironment in lung adenocarcinoma. ○
- 86 Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer. ○
- 85 Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. **2023**, 615, 697-704 ○
- 84 MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression. 14, ○
- 83 Current Advances in Immune Checkpoint Therapy. ○
- 82 DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysis. ○



- 81 A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy. **2023**, 24, 5332 ○
- 80 Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment. 3, ○
- 79 Anti-PD-(L)1 therapy of non-small cell lung cancer: A summary of clinical trials and current progresses. **2023**, 9, e14566 ○
- 78 Genetic and immune microenvironment characterization of HER2 -positive gastric cancer: Their association with response to trastuzumab-based treatment. ○
- 77 Persistence is key: Refining immunotherapy response prediction. **2023**, 56, 472-474 ○
- 76 SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation. **2023**, 8, ○
- 75 Case report: POLE (P286R) mutation in a case of recurrent intestinal leakage and its treatment. 13, ○
- 74 The current understanding of the immune landscape relative to radiotherapy across tumor types. 14, ○
- 73 Characterization of pancreatic cancer with ultra-low tumor mutational burden. **2023**, 13, ○
- 72 Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. ○
- 71 Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer. 14, ○
- 70 Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors. 14, 117-130 ○
- 69 Pan-cancer analysis of co-inhibitory molecules reveals their potential prognostic and clinical values as biomarkers. ○
- 68 Propagated Circulating Tumor Cells Uncover the Potential Role of NF $\kappa$ B, EMT, and TGF $\beta$  Signaling Pathways and COP1 in Metastasis. **2023**, 15, 1831 ○
- 67 Non-Oncogene Addiction of KRAS-Mutant Cancers to IL-1 $\beta$  via Versican and Mononuclear IKK $\alpha$  **2023**, 15, 1866 ○
- 66 Definition of a Novel Immunogenic Cell Death-Relevant Gene Signature Associated with Immune Landscape in Gastric Cancer. ○
- 65 Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. ○
- 64 FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer. **2023**, 15, 1901 ○

- 63 Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. 13, ○
- 62 Combi-TED: a new trial testing Tedopifi with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. **2022**, 18, 4457-4464 ○
- 61 Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma. **2023**, 23, 361-368 ○
- 60 Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. **2023**, 23, ○
- 59 Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells. **2023**, 15, 1934 ○
- 58 Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma. 14, ○
- 57 Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. ○
- 56 T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. **2023**, 4, 58-72 ○
- 55 Immune Checkpoint Blockade Response Biomarkers. **2023**, 1-34 ○
- 54 Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy. ○
- 53 Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. **2023**, 22, ○
- 52 Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures. **2023**, 18, 396-398 ○
- 51 Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. **2023**, 11, 1020 ○
- 50 Precision Oncology: Evolving Clinical Trials across Tumor Types. **2023**, 15, 1967 ○
- 49 Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. **2023**, 13, ○
- 48 An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma. **2023**, 13, ○
- 47 Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. **2023**, 14, ○
- 46 Targeting the Molecular and Immunologic Features of Leiomyosarcoma. **2023**, 15, 2099 ○

- 45 Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix. **2023**, 33, 623-627
- 44 Re-evaluating the melanoma TIL compartment and its unexpected spectrum of exhausted and functional T cells.
- 43 Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.
- 42 Advancing Cancer Immunotherapy Through Integrating Molecular and Computational Approaches. **2023**, 1-22
- 41 The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens. **2023**, 67, 101758
- 40 Nueva actualizaci3n de las recomendaciones para la determinaci3n de biomarcadores predictivos en el carcinoma de pulm3n no c3lula peque1a: Consenso Nacional de la Sociedad Espa1ola de Anatom3a Patol3gica y de la Sociedad Espa1ola de Oncolog3a M3dica. **2023**, 56, 97-112
- 39 Pan-cancer analysis of super enhancer-induced PRR7-AS1 as a potential prognostic and immunological biomarker. 14,
- 38 Mechanisms of Autoimmunity. **2023**, 649-656
- 37 The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating.
- 36 Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. 14,
- 35 Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
- 34 Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting.
- 33 Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073
- 32 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194
- 31 Neoantigen-directed therapeutics in the clinic: where are we?. **2023**,
- 30 Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. **2023**, 21,
- 29 Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer. 14,
- 28 An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. **2023**,

- 27 T Cell Based Immunotherapy for Cancer: Approaches and Strategies. **2023**, 11, 835 ○
- 26 Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer. 14, ○
- 25 Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level. **2023**, 34, 327-332 ○
- 24 Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer. ○
- 23 Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression. **2023**, 33, 101671 ○
- 22 Investigation of Diagnostic and Prognostic Value of CLEC4M of Non-Small Cell Lung Carcinoma Associated with Immune Microenvironment. Volume 16, 1317-1332 ○
- 21 Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. ○
- 20 Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma. 13, ○
- 19 Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer. Volume 16, 1693-1709 ○
- 18 Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. **2023**, 562, 216182 ○
- 17 Multi-omics analysis reveals prognostic and immune characteristics of cuproptosis in lung adenocarcinoma. ○
- 16 Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. **2023**, ○
- 15 A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. 14, ○
- 14 Early Changes of Serum Interleukin 14 $\beta$  Levels Predicts the Response to Anti-PD-1 Therapy in Cancer. **2023**, 17, 117955492311633 ○
- 13 Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. **2023**, 24, 7577 ○
- 12 Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. **2023**, 154470 ○
- 11 Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. **2023**, 24, 7640 ○
- 10 Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer. **2023**, 13, ○

- 9 Gut microbiome and cancer implications: Potential opportunities for fermented foods. **2023**, 188897 ○
- 8 bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer. **2023**, 91, 104564 ○
- 7 Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness. 14, ○
- 6 Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy. ○
- 5 Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study. Volume 15, 311-325 ○
- 4 Linked CD4+/CD8+T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression. ○
- 3 Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. ○
- 2 Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country. **2023**, 30, 107327482311752 ○
- 1 Research Progress of Serum Tumor Markers in Esophagogastric Junction Cancer. **2023**, 13, 7652-7658 ○